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Investigating the role of cholesterol metabolism and synthesis in metastasis and 
radiation response in aggressive subtypes of breast cancer 
Adam Ross Wolfe, B.S. Advisory Professor: Wendy A. Woodward, MD,PhD 
Aggressive breast cancers, triple-negative breast cancer (TNBC) and inflammatory 
breast cancer (IBC), metastasize at a high rate and are notoriously resistant to standard 
treatments. Research has shown diets high in cholesterol increase the incidence of aggressive 
breast cancers and pre-clinical research has shown cholesterol can fuel the growth of breast 
cancer in vivo. Studies at MD Anderson have shown that IBC patients taking cholesterol 
lowering drugs, statins, have improved survival outcomes, and also statins can improve the 
response to radiation in vitro. Furthermore, statins have been shown to target the cells with stem 
like-properties called cancer stem cells (CSCs) which are known to be important in the 
pathogenesis of aggressive breast cancers. However, the effects of statins specifically on TNBC 
metastasis and the mechanism of action have not been explored. Furthermore, the transporters of 
cholesterol, high-density (HDL) and very low-density (VLDL) lipoproteins, have not been 
studied extensively in aggressive breast cancers. Due to the associations with cholesterol and 
incidence of breast cancer and the work done with statins and IBC, I hypothesized reductions in 
intracellular cholesterol content by statins or HDL inhibits downstream signaling regulating 
metastasis and radiation response, altering cellular functions in cancer cells and immune cells. 
Here I show for the first time that statins can inhibit TNBC cell metastasis in vivo, and is 
dependent on FOXO3a activation, demonstrate a potential role for dyslipidemia in radiation 
sensitivity and survival among IBC patients, reveal miR-33a regulates HDL-induced radiation 
sensitivity in breast cancer, and mesenchymal stem cells (MSCs) and macrophages can 
influence each other to increase the tumor promoting influence of each on IBC cells which can 
be inhibited with statins. 
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1.1 Brief History of Breast Cancer 
Breast cancer, in ancient Greece, was believed to be caused by dark and mysterious 
“black bile” circulating in the blood. The treatment of breast cancer in the Middle Ages was 
gruesome, including the usage of bloodletting, sulfur, and arsenic which did more harm than any 
good. It wasn’t until the turn of the 19th century that the idea of “transformed” normal cells 
being the cause of breast cancer took hold. The famous surgeon William Halsted in the late 
1800s revolutionized the treatment of breast cancer, submitting the hypothesis that malignant 
breast cancer spread outward by invasion from the original tumor mass and therefore only 
“radical” mastectomy could hope to cure the patient. This surgery involved the surgical removal 
of the entire breast tissue, pectoralis major and minor muscles, and lymph nodes of the axilla. 
This surgery left women disfigured and the surgery only provided a 20-year survival rate of 
50%.1  It wasn’t until the 1970s that clinical trials showed that less radical surgeries had the 
same survivorship rates.  
 During the time of Halsted’s radical mastectomy, Wilhelm Conrad Röntgen discovered 
the X-ray for which he received the first Nobel Prize in physics.2  Emil Grubbe was still in 
medical school remarkably when he first used X-rays to treat a woman with breast cancer in 
1896. Marie Curie, the first women to win the Nobel Prize, discovered two new elements, 
polonium and radium, which would become to be widely used in the early 1900s for neoplasms 
including breast cancer. Radium was replaced with cobalt therapy and caesium units in the mid-
1900s.2 Now the majority of breast cancers are treated with 3-D conformal therapy utilizing 
both photons and electrons. The use of intensity-modulated radiation therapy (IMRT) and 
protons are also being researched for their potential use in breast cancer.  
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At the end of World War II, sailors coming home exposed to mustard gas during the war 
were discovered to have toxic effects on their bone marrow. Thus, the era of chemotherapy 
began with the use of nitrogen mustard to treat lymphoma.3 In the 1950s in Boston, Sidney 
Farber showed folic acid compounds could cause remissions in children with acute leukemia. 
Clinicians Emil Frierech and Emil Frei introduced the idea, albeit to the horror of the medical 
community, of combination chemotherapies which sent children with leukemia to near-death 
but had the intended results of long-term remissions in children with acute lymphoblastic 
leukemia (ALL).3  From that point in history several classes of chemotherapies were discovered 
and tailored to breast cancer patients including drugs still used today including, doxorubicin, 
cyclophosphamide, and taxanes. 
 The last class of drugs used for breast cancer is hormonal therapy. At the turn of the 20th 
century Thomas Beatson in England discovered that performing an oophorectomy in women 
with advanced breast cancer prolonged their lives.4 His discovery revealed that the ovarian 
produced hormone, estrogen, had a pro-tumor effect on breast cancer. This same phenomenon 
was later shown 50 years later in prostate cancer by the testicular produced hormone, 
testosterone.  Today, a drug that blocks the binding of estrogen to its receptor, Tomoxifen, is 
standard of care for all estrogen receptor (ER) positive breast cancer patients.4   
All of these discoveries bring us to where we are today in the treatment of breast cancer. 
The three headed arsenal of surgery, radiation, and chemotherapy has given what was once 
thought impossible to breast cancer patients, a cure. Unlike some of the other stubborn cancers, 
such as pancreatic cancer, breast cancer death rates have plummeted over the past 20 years. The 
remaining battle in breast cancer is against what we in the field have labeled “aggressive breast 
cancers.”  
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1.2 Aggressive breast cancers 
Aggressive breast cancers fall into two non-mutually exclusive classifications. The first 
is triple-negative breast cancer (TNBC), and the second being inflammatory breast cancer 
(IBC). TNBC is distinguished due to its lacking histologically of progesterone receptor (PR), 
ER, nor overexpression of  human epidermal growth factor receptor 2 (HER2/neu). Between 12-
15% of breast cancers in the United States annually will be of the TNBC subtype. TNBC 
patients have poor prognostic factors including disease-free survival (DFS) and overall survival 
(OS). More frequently compared to the other subtypes, TNBC occurs in younger women (<45) 
and African American women.5 Strikingly, 75% of TNBC are “basal-like”.6 Some often 
interchange the two. Basal-like tumors are higher grade and more aggressive.7 TNBC tumors 
have shortened disease free interval in the adjuvant and neoadjuvant setting and act more 
aggressively in the metastatic setting.8 They are highly resistant to chemotherapies and have a 
higher propensity to metastasize to the brain compared with luminal subtypes.9 A major 
viewpoint in the field is that the basal subtype of breast cancer represents a more 
undifferentiated stem cell like population compared to the luminal subtype. Cancer stem cells 
(CSCs) are known to be resistant to chemotherapy and radiation, initiate metastasis, and 
repopulate tumors after more differentiated cells are eliminated.10 The strong correlation 
between TNBC and the basal subtype leads to the speculation that TNBC contains a larger stem-
cell like population compared to non TNBC thus leading to its aggressiveness.  
 IBC is the second class of aggressive breast cancer. The term inflammatory was added to 
the name because of the striking sudden appearance of an inflammatory like reaction of the 
breast that doctors even today misdiagnosis as mastitis. IBC comprises approximately 5% of all 
breast cancer cases but accounts for 10% of breast cancer mortalities.11 IBC presents rapidly 
with the development of skin symptoms, including redness and skin edema identified by 
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prominent dermal hair follicles (peau d’orange), instead of as a mass detected by palpation or 
mammography. In IBC, the affected breast is often swollen, and nipple retraction is also 
common.12 The percentage of IBC patients with TNBC is higher than non-IBC patients which 
suggest there is some overlap between these types of aggressive types of breast cancer. Like 
TNBC, IBC is found to be enriched in cancer stem cell signatures.13 The key to understanding 
the biology of these aggressive breast cancers and developing better treatment options might 
well in fact be found in the well-known observation that obese women are statistically more 
likely to develop not just breast cancer, but aggressive breast cancers such as TNBC and 
IBC.14,15  
1.3 Role of Cholesterol in Aggressive Breast Cancer 
Western women are five times more likely than women in the developing world to 
develop breast cancer.16 This is most likely due to western diets considering women that migrate 
to the U.S. from the developing world increase their rate of breast cancer to the rate of U.S. 
women.17 Western diets contain high amounts of fats and cholesterol. Is there a connection 
between dietary cholesterol and breast cancer? Several clinical and pre-clinical studies lead us to 
believe that indeed there is.   
In patient data, obesity increases the risk of post-menopausal ER positive breast cancer 
by 50%.14 Cholesterol was shown to be an independent risk factor of breast cancer.18 Post-
menopausal women with the top quartile of cholesterol ingestion had a 50% increase risk of 
breast cancer.19 Llevarias et al in a set of in vivo experiments showed a cholesterol-rich diet 
exacerbates breast cancer progression and metastasis. PyMT female mice were fed a 
cholesterol-rich diet or regular chow diet for 12 weeks. The mice that received the cholesterol-
rich diet had almost twice the amount of tumors as the regular diet mice.20 More importantly the 
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tumors that developed in the cholesterol heavy diet were poorly differentiated and of higher 
histological grade with more angiogenesis. These mice developed more lung metastasis as 
well.20 Nelson and colleagues set out to determine the mechanism by which elevated cholesterol 
is associated with increased breast cancer risk. Using the PyMT breast cancer model they 
showed that a byproduct of cholesterol, 27-hydroxycholesterol, acted much like estrogen to 
enhance breast cancer growth in vivo. The aggressiveness of the tumors was directly correlated 
with the expression of the enzyme that makes this metabolite of cholesterol.21 While these 
studies showed that cholesterol promoted ER+ tumor growth, we are more interested in how 
cholesterol affects the more aggressive breast cancers.  
One of the only studies to focus on the differences of cholesterol metabolism in IBC vs 
non-IBC was performed by Martin et al. They found both non-IBC and IBC cells had increased 
cholesterol content compared with normal mammary epithelial cells. Importantly, IBC cells 
retained high cholesterol stores in the presence of a lipid-deficient environment, while the non-
IBC cells decreased their lipid and cholesterol content in this same environment.22 They 
proposed breast cancer cells would migrate when they no longer could obtain extracellular 
cholesterol. What we found important from this study was that IBC cells had the ability to 
produce de novo cholesterol in the face of depleted cholesterol environments. The rate-limiting 
step in de novo cholesterol synthesis is the enzyme 3-hydroxy-3-methyl-glutaryl-CoA (HMG-
CoA) reductase.23 The inhibition of this enzyme has been utilized for cardiovascular disease for 
decades. This class of drugs, statins, is now being studied for their use in cancers including 
breast cancer.  
1.4 Statins and Breast Cancer 
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Statins lower serum cholesterol and are effective therapies for patients with 
hypercholesterolemia. Because of the association of obesity and high cholesterol diets with 
breast cancer, statins have been studied for the correlation with incidence of breast cancer. 
There are conflicting evidence of statin use and breast cancer incidence, however; the majority 
of evidence support that statins can reduce breast cancer incidence and improve outcomes. A 
Danish study comparing local recurrence rates for stage I-III breast cancer between simvastatin 
users and nonusers showed a significant reduction in recurrence rates in the statin users after 10 
years of follow-up.24 Evidence from other cohort studies suggests that overall disease-free 
survival is improved in patients on statin therapy at the time of cancer diagnosis.25 The pre-
clinical data is massively extensive supporting statins as inhibitors of breast cancer. The anti-
breast tumor effects have centered on the ability of statins to reduce the concentrations of the 
downstream molecule of HMG-CoA reductase, mevalonate. Mevalonate is a major precursor for 
several important cell processes including dolichol, geranylpyrophosphate (GPP), farnesyl-
pyrophosphate (FPP).26 GPP and FPP are critical for isoprenylation of G-proteins Ras and Rho, 
which are important in breast cancer proliferation, apoptosis, and motility.27 Statins were shown 
to block cell-cycle progression in breast cancer by upregulating cell cycle inhibitors p27 and 
p21.28 Statins can inhibit metalloproteinases,29 decrease VEGF secretion from endothelial cells 
25-27,30,31 and induce proapoptotic protein expression, Bax and Bim.28  
 In addition to their general anti-tumor effects in breast cancer, statins have been shown 
to target breast CSCs. Ginestier et al found CSCs were enriched in the mevalonate metabolic 
pathway. Using statins they showed a reduction in CSC formation through inactivation of RhoA 
and accumulation of p27 in the nucleus.32 The proposed importance of CSCs and the 
aggressiveness of breast cancer underscore the value of statin therapies in the clinic. 
Interestingly, in a retrospective analysis of 723 IBC patients from MD Anderson Cancer Center, 
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treatment with a hydrophilic statin was associated with significantly longer progression-free 
survival (PFS) than no statin.33 Our lab showed that statins could be a good therapeutic option 
for IBC patients treated with radiation. The use of statins in a 519 IBC patient cohort reduced 
local regional recurrence (LRR) by 50% following radiotherapy. Multivariate analysis 
demonstrated an association of reduced local recurrence rates with statin use.34 Simvastatin 
radiosensitized both TNBC non-IBC and IBC cells in vitro as well.  
 Statins are not the only way to lower serum cholesterol levels. To fully understand 
cholesterol metabolism, we need to understand the molecules that transport cholesterol from the 
point of ingestion to periphery tissues and back for storage in the liver. These proteins are 
named lipoproteins.  
1.5 Lipoproteins and Breast Cancer 
In the liver free cholesterol is packaged along with triglycerides and apoliporotein B into 
very low-density lipoproteins (VLDL) and secreted into the blood. The resulting VLDL is 
further processed by hepatic lipase yielding low-density lipoproteins (LDL). LDL transports the 
cholesterol to the periphery tissue. LDL binds to the LDL receptor and is internalized by the 
periphery cells. Inside the periphery cells cholesterol concentrations are monitored by the sterol 
regulatory element-binding protein 1 (SREBP) which regulate genes that modulate intracellular 
cholesterol including ATP-binding cassette A1 (ABCA1) and ABCG1 transporters and miR-33. 
Cholesterol is effluxed out of the cell through the ABCA1 and ABCG1 transporters to 
apoliporotein A which forms a mature high density lipoprotein (HDL). HDL then transports 
cholesterol back to the liver where it is stored or excreted.35-38 The concentrations of 
lipoproteins can have positive or negative effects depending on which lipoprotein is elevated. 
Increased LDL and VLDL are known to cause increased arthrosclerosis and HDL the reverse. 
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One of the beneficial effects of statins is that they lower circulating LDL and increase 
circulating HDL.39  
While statins have been extensively looked at in breast cancer, lipoproteins have not 
been. One study have found low levels of  HDL was associated with breast cancer risk.40 The 
link between LDL and breast cancer has been both prognostic and non-significant.41 This 
suggests that lipoproteins might not have an effect on all subtypes of breast cancer. There have 
been limited studies to date looking at specifically in regards to either TNBC or IBC how 
lipoproteins effects breast cancer treatment resistance.    
1.6 Breast Cancer Stem Cells 
Normal stem cells are defined by three characteristics: self-renewal, differentiation into 
multiple lineages, and long lived proliferative potential. In the past 15 years, the identification of 
a small population of cells within solid tumors that closely parallels normal stem cell properties 
were identified and termed “cancer stem cells”.42 The first studies showed that there are 
biologically distinct “tumor-initiating” cells of the breast43, brain44, and hematological 
system45,46 that when orthotopically transplanted into immunocompromised mice regenerate 
solid tumors with neoplastic cells that demonstrate cellular heterogeneity. More recently, several 
studies of normal mammary gland stem cells have highlighted potential limitations of 
transplantation and called into question the use of this assay as the gold standard for 
demonstrating stem cell potential.47-49 However reviewing the sum of both approaches, Visvader 
and Stingl suggest transplantation may unleash a breadth of potential that in vivo is truly only 
seen at specific moments in development.50 It is proposed that these cells in cancers mediate 
recurrence both through their ability to repopulate the tumor with cellular heterogeneity and 
through innate survival mechanisms to resist therapy.  Since CSCs are important in resistance to 
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chemotherapy and radiation, drugs that can target CSCs will be of great importance in 
aggressive breast cancers. 
1.7 The IBC Microenvironment 
The study of IBC would be incomplete without understanding how the 
microenvironment influences and supports IBC. IBC presents uniquely with rapid onset of 
breast swelling and erythema, but is virtually indistinguishable from non-IBC at the pathologic 
and molecular level.51-53 One difference was discussed earlier; IBC cells have a unique ability to 
regulate intracellular cholesterol which is vital for its growth and invasion.22 Understanding how 
the IBC microenvironment influences IBC incidence and progression will lead us to improving 
the outcomes in IBC patients. But first we need to review the important players in the 
microenvironment.  
The hematopoietic stem cell (HSC) niche has been elucidated. The HSC niche is 
organized around a collection of normal and malignant cells in the bone marrow that coordinate 
between direct cell contact, hypoxia, and secreted factors.54 A crucial player in the HSC niche is 
the nestin+ mesenchymal stem cell (MSC). In the niche, macrophages support the maintenance 
of MSCs.54 There seems to be a symbiotic relationship between MSCs and macrophages that 
were highlighted by mouse studies showing macrophage depletion lead to the elimination of the 
HSC niche.55 There is no current evidence of a similar IBC stem cell niche. However, we 
believe the current evidence supports the idea of a similar situation happening in IBC 
environment.  
MSCs promoted IBC stem cells and in vivo tumor growth.56 Our group further showed 
that MSCs could promote the IBC phenotype in vivo. Injecting MSCs with IBC cells into the 
mammary fat pad led to the hallmark pathological and skin erythema found in patients.57 These 
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results suggest MSCs have a unique role in IBC promotion, but we do not yet know if 
macrophages also play a role similar like in the HSC stem cell niche. Macrophages infiltrating 
the breast tumor, or tumor associated macrophages (TAMs), demonstrated a negative correlation 
with breast cancer outcome.58 TAMs have been shown in vivo to promote lymphatic emboli, the 
hallmark of IBC.59 The state and plasticity of macrophages (tumor or normal adjacent) in IBC 
patients and models has not been examined nor has their interaction with other cell types in the 
IBC stroma been examined. Lack of such knowledge is important because these cells are 
potentially mediators of field effects that lead to the clinical characteristics of IBC, and targets 
for prevention and treatment of IBC.  
1.8 Conclusions 
 This introductory chapter described the status of present day breast cancer treatment and 
the subtypes of breast cancer that still provide poor survival outcomes. Cholesterol was shown 
to be critical for the aggressiveness in breast cancers. The possible mechanisms through which 
cholesterol can impact breast cancer growth and metastasis was discussed. Also, the patient data 
was reviewed to show the relationship between high cholesterol diet and breast cancer incidence 
and outcomes. Next the statin data on breast cancer was discussed. Statins inhibit de novo 
cholesterol synthesis and several studies have shown their anti-tumor effect in breast cancer. 
Our group showed in IBC, statin users had better outcomes and statins radiosensitized IBC cells 
in vitro. The transporters of cholesterol, lipoproteins, were examined next. HDL, VLDL, and 
LDL mediate plasma and cellular cholesterol concentrations and studies suggest HDL might 
have a protective role in breast cancer.  Breast CSCs are thought to be a driving force in 
aggressive breast cancers. A brief overview of the theory of CSCs was presented. Lastly, the 
IBC microenvironment was discussed. The lack of molecular differences between IBC and non 
IBC suggest something inherent in the normal breast is driving this aggressive phenotype. We 
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presented two stromal cells, macrophages and MSCs, that we believe play an important role in 
IBC.  
1.9 Conceptual Framework and Hypothesis 
 The main goals of this thesis include challenging the current belief that the effects of 
statins in breast cancer are cholesterol independent inhibition of GPP and Ras prenylation. The 
concentrations of statins being used in existing studies might be too high to be relevant in 
patients. The inhibition of Ras, Rho, and Rap prenylation by statins requires a concentration as 
high as 50 µM. However, therapeutic levels of statins (50 nM to 3µM) do not.60 So the first aim 
of this thesis will be to study how a therapeutic concentration of a statin impacts TNBC 
metastases. Next, targeting cholesterol metabolism is an exciting proposition for aggressive 
breast cancer. Cancer cells require cholesterol for sustained proliferation and oncogenic 
signaling. Upsetting the tumor cell’s ability to acquire and maintain cholesterol is a possible 
preventive and therapeutic strategy. Because radiation is a key component to aggressive breast 
cancer care, the second and third aims will focus on how disturbing cholesterol concentrations 
through lipoproteins changes radiation sensitivity. The final aim will look to understand how the 
tumor microenvironment plays a significant role in IBC and if statins can disrupt this IBC 
environment.  
To summarize the entirety of my thesis, the central hypothesis is reductions in intracellular 
cholesterol content by statins or HDL inhibits downstream signaling regulating metastasis and 
radiation response, altering cellular functions in cancer cells and immune cells. To test this 
hypothesis I investigated specific aims: 
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1. To demonstrate that statins reduce the incidence of breast cancer metastasis in vivo and 
characterize relative mechanistic signaling: 
a. Characterize in vitro and in vivo effects on metastasis of physiologic 
concentration of statins in aggressive breast cancer models 
b. Investigate mechanistic signaling pathways involved in statins in aggressive 
breast cancer 
2. To characterize changes in IBC cellular cholesterol through lipoprotein treatment alters 
self-renewal capacity and radiation sensitivity. 
a. Characterize the effects of lipoproteins on in vitro stem cells and radiation 
response 
b. Demonstrate lipoprotein effects on signaling pathways  
3. To establish that differences in miR-33a expression in breast cancer cell line lines 
correlates to their radiation sensitivity to the exposure to HDL in vitro. 
a. Manipulate the expression of miR-33 expression in high and low expressing 
breast cancer cell lines 
b. Demonstrate radiation sensitivity in the presence or absence of HDL. 
4. Demonstrate MSCs and Macrophages cross talk through cytokines to promote the 
Inflammatory Breast Cancer phenotype and can be inhibited by statins 
a. To demonstrate tumor promoting macrophages change the MSC cytokine and 
migration potential (“educated MSCs”) 
b.  To elucidate if macrophage educated MSCs increase IBC invasion and sphere 
formation 
c. To characterize that statins block the MSC promotion of the IBC phenotype 
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Chapter II 
Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models 
through regulation of FOXO3a 
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2.1 ABSTRACT  
Purpose: Statins are being explored for their potential use in prevention of breast cancer. The 
purpose of our study was to examine the effect of statins on triple negative breast cancer 
(TNBC) cells metastatic potential.  
Experimental Design: TNBC cells were treated with simvastatin and then studied for cell cycle 
progression and proliferation in vitro, and metastasis formation in vivo, following injection of 
statin-treated cells. Reverse-phase protein assay (RPPA) analysis was performed on statin-
treated and control breast cancer cells. RNA interference targeting FOXO3a was used to 
measure the impact of simvastatin on FOXO3a-deficient SUM149 cells. The prognostic value of 
FOXO3a mRNA expression was examined in 8 public breast cancer gene expression data sets 
including 1,479 patients.  
Results: Simvastatin increased G1/S phase arrest of the cell cycle and inhibited both 
proliferation and migration of TNBC cells in vitro. In vivo, pretreatment with simvastatin 
reduced metastases formation in both orthotopic-injection (p=0.017) and tail-vein-injection 
models (p=0.04). Phosphorylated FOXO3a was downregulated after simvastatin treatment in 
(RPPA) analysis. Ectopic expression of FOXO3a in low-expressing SUM159 cells enhanced 
mammosphere formation (p=0.005) and migratory capacity (p=0.14) in vitro. Consistently, 
knockdown of FOXO3a in high-expressing SUM149 cells attenuated the effect of simvastatin 
on mammosphere formation and migration. Furthermore, tumor FOXO3A mRNA 
downregulation was independently associated with shorter metastasis-free survival in all breast 
cancers, as well as in TNBC breast cancers. 
Conclusions: Simvastatin can inhibit breast cancer cell metastasis in vivo, and is dependent on 
FOXO3a activation. Furthermore, high FOXO3a levels in patients predicted for longer distant 
free metastasis survival.  
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2.2 Introduction 
Metastasis is the most common cause of death among women with breast cancer. Triple-
negative breast cancer (TNBC) comprises 15% of breast cancers and has the poorest survival 
outcome of all breast cancer subtypes due to the high propensity for metastatic progression 61 
and absence of specific targeted treatments. Breast cancer metastases develop from 
dissemination of primary tumor cells into distant organs. The primary tumor cells most likely to 
metastasize are hypothesized to be cancer stem cells (CSCs). CSCs have unlimited self-renewal 
potential, can generate non-CSC progeny, are resistant to conventional therapies, and are 
capable of migration 10,62. In xenograft models of breast cancer, breast CSCs (i.e., cells 
expressing CD44) displayed increased metastasis compared to CD44- breast cancer cells 63,64. 
Recently, Ginestier et al. showed statins (3-hydroxyl-3-methyl glutaryl coenzyme A 
reductase inhibitors) regulate breast CSCs through inhibition of RhoA 32. Statins are widely 
used to reduce cholesterol and lipoprotein levels and thereby reduce mortality from 
cardiovascular disease; recently, statins have also been studied for their impact on cancer. A 
Danish study comparing local recurrence rates for stage I-III breast cancer between simvastatin 
users and nonusers showed a significant reduction in recurrence rates in the statin users after 10 
years of follow-up 24. We showed previously that simvastatin radiosensitized triple negative cell 
lines in vitro 65. Statins have also been shown to have clinical benefits in lung, prostate, and 
colon cancer 66-68.  The mechanisms underlying the antitumor effects of statins have been 
studied extensively. Statins decrease EGFR dimerization 69, increase inducible reactive nitric 
oxide level 70, reduce metalloproteinase levels 29, decrease synthesis of inflammatory cytokines 
71
, and reduced VEGF secretion in breast cancer models 72. Statins effect on metastasis and its 
underlying mechanisms are unknown. 
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Herein we determined the effect of statins specifically on TNBC metastasis and 
observed inhibition of metastasis by statins. Further, we identified FOXO3a as a potential 
mediator of TNBC metastasis using in vitro and in vivo models, and show that statin therapy 
regulates FOXO3a activation, suggesting a potential mechanism for simvastatin’s anti-
metastatic effects. 
 
2.3 Materials and Methods 
Cell Culture and Drugs. SUM149 and SUM159 breast cancer cells were obtained from Asterand 
(Detroit, MI) and passaged in the laboratory for fewer than 6 months after receipt.  Both types of 
cells were cultured in Ham’s F12 medium supplemented with 10% fetal bovine serum, 1 µg/mL 
hydrocortisone, 5 µg/mL insulin, and 1% antibiotic-antimycotic. MDA-231 cells were obtained 
from ATCC and were cultured in α-media supplemented with 10% FBS, 1 µg/ml 
hydrocortisone, 1 µg/ml insulin, 12.5 ng/ml epidermal growth factor, sodium pyruvate, 
nonessential amino acids, 2 mM glutamine, and 1% antibiotic-antimycotic. Simvastatin (Sigma) 
was dissolved in DMSO at a stock concentration of 5 mM and stored at −80°C, and a final 
concentration of 2.5 µM was used in this study. DMSO alone was used as a control.   
Mammosphere Formation Assay. Mammosphere formation has been used as a measure of the 
self-renewal capacity of breast CSCs and correlates closely with tumorigenicity 73. Treated and 
control cells were grown in standard mammosphere medium (serum-free, growth-factor-
enriched medium) in low attachment plates at a concentration of 20,000 cells/mL. For secondary 
mammosphere assay, cells from primary mammospheres were dispersed with 0.05% trypsin, 
seeded in ultra-low attachment plates (20,000 cells/mL) in mammosphere medium, incubated 
for 7 days, and counted. 
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Aldefluor Assay. To further investigate the self-renewal capacity of cells, we used the Aldefluor 
assay following the manufacturer’s guidelines (StemCell Technologies, Vancouver, Canada). 
Briefly, 5 x 105 cells were suspended in Aldefluor assay buffer containing ALDH substrate and 
incubated for 30 min at 37°C. As a negative control for each sample, cells were incubated with 
50 mmol/L specific ALDH inhibitor diethylamino benzaldehyde (DEAB). Aldefluor 
fluorescence was excited at 488 nm, and fluorescence emission was detected using a Beckman 
Coulter machine. The data files were analyzed using FlowJo software (Treestar, Ashland, OR). 
For sorting, gates were established using ALDH-stained cells treated with DEAB as negative 
controls and taking the high negative and positive cells. 
Cell Cycle Distribution and Cell Proliferation Assays. For assessment of cell cycle distribution, 
cells were fixed dropwise with 70% ice-cold ethanol overnight at 4°C. Then cells were 
suspended in 100 µL of phosphate-citrate buffer (0.19 M Na2HPO4, 4 mM citric acid), 
incubated for 30 min at room temperature, and resuspended in PBS containing 10 µg/mL 
propidium iodide and 10 µg/mL RNase A. The propidium iodide-stained cell samples were 
analyzed using FACSCalibur (Becton-Dickinson, San Jose, CA), and the percentage of cells in 
each phase of the cell cycle (G1, S, and G2/M) was analyzed with CELLQuest (Becton-
Dickinson). For proliferation assay, pre-treated or DMSO treated cells were seeded at a density 
of 1.0 × 104 in 6 cm plates. After the specified number of days (24h-8 days), cells were 
trypsinized and viable cells counted with a Cellometer automated cell counter. 
Migration assays. Cellular migration assays were performed using a Boyden chamber 
containing 24-well Transwell plates (Corning Inc.) with 8-µm pores on the membrane. All 
experiments were performed in duplicate and repeated three times. Approximately 5 × 104 cells 
in 200 µL culture medium supplemented with 10% FBS were seeded into the upper chamber. 
The lower chamber was filled with 500 µL complete medium (with 10% FBS) as a 
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chemoattractant plus or minus simvastatin. After 24 hours of incubation at 37°C in a 5% CO2 
atmosphere, the membranes containing the cells were fixed and stained with crystal violet. The 
lower surfaces of the membranes were photographed at × 100 magnification. Five random fields 
were photographed for each chamber to determine the migration. 
In Vivo Studies. Four-week-old female SCID/Beige mice (Harlan, USA) were housed and used 
in accordance with guidelines of The University of Texas MD Anderson Cancer Center under 
an Institutional Animal Care and Use Committee-approved protocol (ACUF 07-08-07213). 
Mice were anesthetized through intraperitoneal injection of a cocktail containing ketamine (100 
mg/kg), xylazine (2.5 mg/kg), and acepromazine (2.5 mg/kg) in sterile saline solution, and fur at 
the surgical site was removed. The number-4 inguinal glands were cleared of mammary 
epithelium, and green fluorescent protein (GFP)-luciferin-labeled control SUM149 cells and 
simvastatin (1.25 µM)-treated GFP-luciferin-labeled SUM149 cells (8.0 x 105 in 15 µL of PBS) 
were injected into the cleared fat pads. Transplants were allowed to grow until tumors reached a 
volume of 500 mm3. Tumor growth was monitored weekly with caliper measurements. Tumors 
were resected under the above-mentioned institutional guidelines. A portion of each tumor was 
formalin-fixed, paraffin-embedded, sectioned, and stained with hematoxylin and eosin. After 
tumor resection, mice were injected weekly with D-luciferin (Biosynth) and imaged weekly for 
metastasis for 6 weeks after resection. Portions of xenografts were formalin-fixed, paraffin-
embedded, sectioned, stained with hematoxylin and eosin, and used for immunofluorescence 
staining to detect FOXO3a. 
To further investigate in vivo metastasis, we used a tail-vein-injection metastasis model. GFP-
labeled SUM149 cells were treated with simvastatin (1.25 µM) in vitro. Twenty-four hours 
later, 1.0 x 106 GFP-labeled simvastatin-treated or DMSO-treated (control) SUM149 cells were 
injected via tail vein into 4-week-old female SCID/Beige mice. Mice were euthanized 8 weeks 
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after injection, and lung and brain metastatic colonization were assessed by fluorescent 
stereomicroscopy. All staining studies were performed with standard protocols, and staining was 
analyzed by a pathologist specializing in breast cancer. 
RPPA Analysis. Cellular proteins were denatured by 1% SDS (with beta-mercaptoethanol) and 
diluted in five 2-fold serial dilutions in dilution buffer (lysis buffer containing 1% SDS). Serial 
diluted lysates were arrayed on nitrocellulose-coated slides (Grace Biolab) by Aushon 2470 
Arrayer (Aushon BioSystems). Total 5808 array spots were arranged on each slide including the 
spots corresponding to positive and negative controls prepared from mixed cell lysates or 
dilution buffer, respectively. Each slide was probed with a validated primary antibody plus a 
biotin-conjugated secondary antibody. All sample analysis was performed at the MD Anderson 
RPPA Core Facility. 
Immunoblotting and immunofluorescence. For immunoblotting, cells were lysed in 1x RIPA 
lysis buffer containing 1 µM PMSF, and 40 µg of protein was electrophoresed on SDS-
polyacrylamide gels with a concentration gradient of 4% to 20% (Invitrogen). Membranes were 
incubated with primary antibodies, anti-FOXO3a, anti-phosphoFOXO3a (Ser253), anti-
CDKN1Bkip1 (Cell Signaling Technology). Actin antibody was used as a loading control. For 
immunofluorescence, xenograft tissue slides were incubated with heated Citrate buffer for 
antigen retrieval. Primary antibody FOXO3a (Cell Signaling) was added overnight at 4C. Slides 
were incubated with GFP labeled anti-rabbit secondary antibodies. The slides were viewed with 
a fluorescent microscopy following DAPI staining (Nikon).  
FOXO3a Knockdown and overexpression. SignalSilence siRNA targeting FOXO3a and 
nontargeting siRNA were purchased from Cell Signaling.  SUM149 cells (100,000/dish) were 
plated on 35 mm dishes. The following day, the cells were transfected with the siRNAs using X-
tremeGENE siRNA Transfection Reagent (Roche) according to the manufacturer’s protocol. 48 
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hours after transfection, cells were washed collected for analysis of FOXO3a levels by western 
blotting and assayed for migration and mammosphere formation. Stable overexpression of 
FOXO3a in SUM159 cell line was conducted using overexpression plasmids purchased from 
Systems Biosciences according to the manufacturer’s instruction. Briefly, overexpression 
FOXO3a plasmids were packaged along with plasmids pRSV-Rev, pMDLg-pRRE and pCMV-
VSVG in 293T cells. Cell lines were then transduced as we described previously 56. 
Gene expression data analysis. We analyzed FOX03A mRNA expression in clinical samples in 8 
public gene expression data sets selected as follows: pre-treatment sample of primary breast 
cancer, with at least one probe set representing FOX03A, and with the following 
clinicopathological annotations (pathological axillary lymph node status pN, tumor size pT, and 
grade, and follow-up in term of metastatic relapse). Data sets were collected from the National 
Center for Biotechnology Information (NCBI)/Genbank GEO and ArrayExpress databases, and 
authors’ website (1). The final pooled data set included 1,479 non-metastatic, invasive breast 
cancers. Their clinicopathological characteristics are summarized in (Table 2). Data analysis 
required pre-analytic processing. First, we normalized each data set separately using quantile 
normalization for the available processed data from the Agilent-based sets, and Robust 
Multichip Average (RMA) 74 with the non-parametric quantile algorithm for the raw data from 
the Affymetrix-based data sets. Normalization was done in R using Bioconductor and associated 
packages. Hybridization probes were then mapped across the different technological platforms. 
We used SOURCE (http://smd.stanford.edu/cgi-bin/source/sourceSearch) and EntrezGene 
(Homo sapiens gene information db, release from 09/12/2008, ftp://ftp.ncbi.nlm.nih.gov/gene/) 
to retrieve and update the Agilent annotations, and NetAffx Annotation files 
(www.affymetrix.com; release from 01/12/2008) to update the Affymetrix annotations. The 
probes were then mapped based on their  
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Table 1: List of breast cancer gene expression data sets included in the analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reference N° of 
samples
N° of 
analysed 
samples*
Technological platform N° of probes Source of data
van de Vijver et al.,
N Engl J Med  2002 254 254 Agilent Hu25k 60mer 25K http://microarray-pubs.stanford.edu/wound_NKI/
van't Veer et al.,
Nature  2002 117 97 Agilent Hu25k 60mer 25K http://www.rii.com/publications/2002/vantveer.html
Ivshina et al.,
Cancer Res  2006 448 243 Affymetrix U133 A+B 2x22K GEO databaseGSE4922_1456
Sotiriou et al.,
JNCI  2006 80 73 Affymetrix U133 A 22K GEO databaseGSE2990
Desmedt et al.,
Clin Cancer Res 2007 154 154 Affymetrix U133 A 22K GEO databaseGSE7290
Merritt WM et al.,
N Engl J Med 2008 130 124 Affymetrix U133AAofAv2 23K Array ExpressdatabaseE-MTAB-158
Schmidt M etal.,
Cancer Res  2008 200 200 Affymetrix  U133A 22K GEO databaseGSE11121
Sabatier et al.,
 PLoS ONE  2011 352 334 AffymetrixU133 Plus 2.0 54K
GEO database
GSE31448
* Only non-metastatic samples (M0)
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Characteristics N (%) 
 
 Age, years   
 <=50 657 (59%) 
 >50 463 (41%) 
 Pathological type * 
 IDC 376 (78%) 
 ILC 35 (7%) 
 MIX 21 (4%) 
 other 48 (10%) 
 Pathological grade 
 1 279 (19%) 
 2-3 1158 (81%) 
 Pathological axillary lymph node status, 
pN 
 negative 866 (66%) 
 positive 443 (34%) 
 Pathological tumor size, pT 
 pT1 607 (48%) 
 pT2-3 653 (52%) 
 ER status 
 negative 403 (27%) 
 positive 1076 (73%) 
 PR status 
 negative 632 (43%) 
 positive 847 (57%) 
 ERBB2 status 
 negative 1313 (89%) 
 positive 166 (11%) 
 Metastatic relapse 
 no 1069 (72%) 
 yes 410 (28%) 
 Median follow-up, months 93 (1-299) 
 5-year MFS [95CI] 77%  [0.75-0.79] 
 
   * IDC, invasive ductal carcinoma; ILC, invasive lobular carcinoma; MIX, mixt 
 
Table 2: Patients and tumor characteristics. 
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EntrezGeneID. When multiple probes mapped to the same GeneID, we retained the one with the 
highest variance in a particular dataset. To avoid biases related to immunohistochemistry (IHC) 
analyses across different institutions and thanks to the bimodal distribution of respective mRNA 
expression levels, estrogen receptor (ER), progesterone receptor (PR), and ERBB2 expressions 
(negative/positive) were defined at the mRNA level using gene expression data of ESR1, PGR, 
and ERBB2 respectively, as previously described 75. Before analysis of FOXO3A expression, 
expression data were standardized within each data set as previously described FOXO3A 76 
expression in tumors (T) was measured as discrete value after comparison with mean expression 
in normal breast samples (NB): downregulation, thereafter designated “down” was defined by a 
T/NB ratio ≤0.5 and no downregulation (“no down”) by a T/NB ratio >0.5.  
Statistical Analysis. All data in graphs are presented as mean (standard deviation). For in vitro 
studies, all data are represented in graphs as means ± SEM. A p-value inferior or equal to 0.05 
in a paired two-sided test was considered statistically significant. For RPPA analysis, we used 
analysis-of-variance models to estimate 1) the overall effects of each treatment on each protein, 
and 2) the overall effects of all treatments combined on each protein. All treatment effects were 
computed using control as a reference. These results were averaged across all cell lines. Then 
the same analyses were repeated for each cell line, to determine which treatments worked the 
best for which cell line. Statistical analyses were conducted using SAS 9.4 for Windows (SAS 
Institute Inc., Cary, NC). Correlations between tumor groups and clinicopathological features 
were analyzed using the Fisher’s exact test. Metastasis-free survival (MFS) was calculated from 
the date of diagnosis until the date of distant relapse, and the follow-up was measured from the 
date of diagnosis to the date of last news for event-free patients. Survivals were calculated using 
the Kaplan-Meier method and curves were compared with the log-rank test. Univariate and 
multivariate survival analyses were done using Cox regression analysis (Wald test). Variables 
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tested in univariate analyses included patients’ age at time of diagnosis (≤50 years vs >50), 
pathological type, axillary lymph node status (pN: negative vs positive), tumor size (pT: pT1 vs 
pT2-3), and grade (1 vs 2-3), ER, PR and ERBB2 statutes, and FOXO3A expression-beased 
group (“down” vs “no down”). Variables with a p-value <0.05 in univariate analysis were tested 
in multivariate analysis. Statistical analysis was done using the survival package (version 2.37) 
in the R software (version 2.15.2; http://www.cran.r-project.org/). We followed the reporting 
REcommendations for tumor MARKer prognostic studies (REMARK criteria) 77. Results with 
P-values less than 0.05 were regarded as significant. 
 
2.4 Results  
Simvastatin Inhibits Breast Cancer Metastatic Related Endpoints In Vitro 
 We analyzed the effects of simvastatin on cell proliferation, cell cycle distribution, and 
cell migration in TNBC cell lines. After 24 hours of pre-treating of SUM149, SUM159, and 
MDA-231 cells with simvastatin, we observed a significant decrease in cell proliferation as 
early as 48 hours and as long as 8 days (Figure 1A, B, C). Simvastatin decreased the S-phase 
fraction and increased G1/S arrest in both SUM149 and SUM159 TNBC cell lines (Figure 1D). 
Next we used the Boyden chamber assay to measure migration of DMSO- or simvastatin-treated 
TNBC cell lines in vitro.  Simvastatin treatment significantly reduced the number of SUM149 
cells, SUM 159, and MDA-231 cells that migrated through the pores in the membrane (Figure 
1E). The migratory ability of simvastatin pre-treated SUM149/SUM159 cells was rescued by 
co-treatment with mevalonate. These results demonstrate simvastatin inhibited surrogates of 
metastasis in vitro in multiple TNBC cell lines. As CSCs have been hypothesized as the 
metastatic initiating cells 62,  we used two in vitro stem cell surrogate assays to test for the effect 
of simvastatin on CSC properties. The mammosphere assay developed by Dontu et al for normal 
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mammary gland has been adapted for cancer cell lines as an assay that correlates to cancer cell 
self-renewal capacity. This has been validated in particular in triple negative breast cancer cell 
lines 32,73. Confirming the findings of Ginestier et al 32, we found that primary sphere formation 
in TNBC cell lines SUM149 and SUM159 cells pretreated with simvastatin were reduced 78% 
and 75%, respectively, compared to DMSO-treated control cells (p<0.01) (Figure 2A, B). The 
addition mevalonate (10 mM), the organic compound downstream of simvastatin inhibition, 
rescued mammosphere formation back to control levels. Similarly, secondary sphere formation 
was inhibited (P<0.01) in simvastatin-treated cells compared to DMSO-treated cells for both 
cell lines. Moreover, the spheres were smaller in simvastatin-treated cells compared to DMSO- 
treated control cells (Figure 2A, 2B). The Aldefluor assay is an alternative surrogate assay to 
test for CSCs 63. We found that the proportions of ALDH-positive cells among simvastatin-
treated SUM149 and SUM159 cells were 23% and 70%, respectively, relative to the proportions 
of ALDH-positive cells among DMSO-treated control cells (P<0.05) (Figure 2C, D). The 
proportions of ALDH-positive cells were also rescued to the levels seen in DMSO-treated 
control cells after administration of mevalonate (Figure 2C, D). Thus, simvastatin reduced two 
independent in vitro surrogates for self-renewal capacity in TNBC cell lines through inhibition 
of the mevalonate pathway. 
  Figure 1. Simvastatin reduces percentage of cycling cells, proliferation, and migration.
Cell proliferation assay conducted to assess proliferation rates in 
(C) MDA-231 cell populations pretreated for 24h with 2.5 µM simvastatin, 10 mM mevalonate, 
both, or vehicle (DMSO).  *, P < 0.05 for unpaired 2
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-tailed Student’s t-test (n = 3).
 
(B) SUM159, or 
 
  Figure 1. Simvastatin reduces percentage of cycling cells, proliferation, and migration.
SUM149 and SUM159 cells were profiled for their cell cycle pattern after they were pretreated 
2.5 µM simvastatin of vehicle for 24 hours and stained with PI. : *, P < 0.05 for unpaired 2
tailed Student’s t-test (n = 3). Abbreviations: PI, propidium iodide
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Figure 1. Simvastatin reduces percentage of cycling cells, proliferation, and migration.
SUM149, SUM159, and MDA
µM simvastatin, 10 mM mevalonate, both, or vehicle (DMSO). 
through the transwell membrane was counted. Significant differences are shown as follows: *, P 
< 0.05 for unpaired 2-tailed Student’s t
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-231 cells migrated through an 8 µm pore in the presence of 2.5 
The number o
-test (n = 3). Abbreviations: PI, propidium iodide.
 
 (E) 
f cells that passed 
 
  Figure 2. Simvastatin reduces the cancer stem cell
SUM159 cells exposed to simvastatin (2.5 µM) treatment (24 h) or simvastatin plus mevalonate 
(10 mM) and seeded in self-renewal promoting suspension culture conditions. There is 
increase in both primary and secondary mammosphere formation in the simvastatin
and spheres were smaller on light microscope (40X). 
follows: *, P < 0.05 for unpaired 2
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-like population. (A) SUM149 and 
Significant differences are shown as 
-tailed Student’s t-test (n = 3).  
 
(B) 
an 
-treated cells 
 Figure 2. Simvastatin reduces the cancer stem cell
illustrating the gating strategy used to isolate ALDH+ 
based on ALDH. Gating is set to DEAB
generated from SUM149 and SUM159
simvastatin or simvastatin plus 10 mM mevalonate or vehicle (DMSO). Results are mean ± 
average number of spheres per 40,000 cells plated ± SEM; representative da
Results are mean ± SEM from at least two biological replicates. 
biological replicates. Abbreviations: ALDH, aldehyde dehydrogenase; DEAB, 
diethylaminobenzaldehyde; DMSO, dimethyl sulfoxide.
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-like population. Flow cytometry plot 
(C) SUM149 and (D) 
-inhibitor control cells. Percentage of 
-sorted ALDH+ cells pretreated for 24h with 2.5 µM 
ta are shown. 
SEM from at least two 
 
 
SUM159 cells 
ALDH+ cells 
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Simvastatin Inhibits Tumor Formation and Metastasis In Vivo 
 To examine the metastatic potential of TNBC cells exposed to simvastatin versus control 
cells, we used two separate in vivo models, an orthotopic xenograft model and an experimental 
metastasis model via tail vein injection. 20 weeks after orthotopic injection, tumors developed in 
67% of the mice injected with simvastatin-treated SUM149 cells compared to 95% of the mice 
injected orthotopically with DMSO-treated SUM149 cells (Table 3, p=0.04). Primary tumors 
were resected at 20 weeks and mice were followed for an additional 8 weeks to evaluate the 
formation of distant metastasis. Of the mice in which tumors developed, 27% of the mice 
injected with simvastatin-treated SUM149 cells had developed metastasis in distant organs 
compared to 79% of the mice injected with DMSO-treated SUM149 cells (Figure 3A, 
P=0.017). Metastasis free survival was thus significantly longer in the simvastatin group 
(Figure 3B, p<0.01) despite no change in the primary tumor growth rate (Figure 4). In the tail-
vein-injection experimental metastasis model, the control group developed distant metastases 
(either lung or brain) at a higher rate than the simvastatin pre-treated group (86% control, 22% 
simvastatin) (P=0.04, Figure 5), confirming that the establishment of colonies within the lung 
or brain was significantly inhibited by simvastatin pre-treatment of the cell lines. 
 Table 3. Tumor incidence and metastasis rate for tail vein and orthotopic in the DMSO control 
and simvastatin-treated SUM 149 group.
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Figure 3. Simvastatin inhibits metastasis in both orthotopic and tail
experiments. GFP labeled SUM149 cells we
injected either orthotopically or into the tail vein of mice and tumor metastasis was assessed. 
(A) Cells were injected into the mammary fat pad and tumor volume monitored every week 
until the tumors reached a volume of 500 mm
measurements (B) Following tumor resection mice were imaged with Luciferin for metastasis 
every two weeks. 
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Figure 4. Simvastatin had no effects on tumor growth rate.
curve for the duration of time from first palpable tumor to time of resection (500 mm3).
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Figure 5. Imaging from mouse injected with SUM 149
weeks after of lung and brain metast
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Simvastatin regulates FOXO3a in TNBC cells 
 To identify pathways targeted by simvastatin we utilized RPPA to compare protein 
activation state in simvastatin treated versus untreated SUM149 and SUM159 cells. We found 
that phosphorylated FOXO3a and Akt were two of several proteins that were significantly 
downregulated (Table 4).  FOXO3a is a known tumor suppressor that is targeted for 
degradation by phosphorylation (27). Akt is activated by phosphorylation following growth 
factor binding to cell membrane receptors such as epidermal growth factor (EGF). Following 
activation Akt regulates FOXO3a through phosphorylation leading to subsequent nuclear 
exclusion and degradation.78 The possibility of increasing expression of a tumor suppressor is 
intriguing so we examined the relative expression of both phosphorylated and total FOXO3a 
and Akt proteins in SUM149 cells treated with simvastatin or vehicle control. We found that 
simvastatin inhibited phosphorylation of FOXO3a and Akt, and simvastatin decreased 
degradation of the total FOXO3a protein in the presence of EGF (Figure 6A). In order to further 
examine the function role of FOXO3a protein in TNBC metastasis, we evaluated its expression 
in three triple negative breast cancer cell lines. We found that SUM149 had a high level of 
FOXO3a expression and SUM159 and MDA-MB-231 had no protein expression of FOXO3a 
(Figure 6B). We used the FOXO3a high-expressing SUM149 and low/non-expressing SUM159 
cell lines for further loss and gain of function experiments to examine whether simvastatin 
suppresses metastases by upregulating FOXO3a.  A model of our working hypothesis is shown 
in Figure 6C. 
 
 
 Table 4. RPPA analysis of simv
SUM159 cells were treated with 2.5 µM simvastatin for 24 hours and submitted for RPPA 
analysis. Analysis-of-variance models were used to estimate 1) the overall effects of each 
treatment on each protein and 2) the overall effects of all treatments combined on each protein. 
All treatment effects were computed using control as a reference. The proteins with a P<0.05 
difference between the control are listed in the table.
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Figure 6. Simvastatin regulates the expression of FOXO3a 
pFOXO3a, anti-FOXO3a antibodies, anti
or 2.5 µM simvastatin or vehicle control. Cells were treated with EGF 10 ng/mL for 15 minute
following 24 hours of simvastatin treatment or DMSO treatment. Beta
loading control. (B) Three breast cancer cell lines were pro
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Figure 6. Simvastatin regulates the expression of FOXO3a
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Next, we stably expressed FOXO3a in the low-expressing SUM159 using a lentiviral 
overexpression vector.  Protein expression of FOXO3a and the downstream target CDKN1B in 
the SUM159 cells was increased compared with SUM159 cells stably transfected with empty 
vector (Figure 7A).   Ectopic expression of FOXO3a significantly inhibited mammosphere 
formation (Figure 7B, p=0.005) and migration of SUM159 cells (Figure 7C p=0.014) in line 
with the effects observed with simvastatin treatment.  
To mimic the effect of high FOXO3a phosphorylation leading to increased degradation, 
we knocked down FOXO3a in the high expressing SUM149 cell and examined the effect of 
simvastatin on these cells lacking FOXO3a. We tested for increased self-renewal and migration 
in vitro following RNA interference targeting FOXO3a in a metastatic TNBC breast cancer cell 
line, SUM149. RNA interference of FOXO3a in SUM149 inhibited the expression of FOXO3a 
(Figure 7D). Knockdown of FOXO3a significantly increased the mammosphere-forming 
efficiency of SUM149 cells compared to control cells (Figure 7E). While pretreatment with 
simvastatin significantly inhibited mammosphere formation in SUM149 cells transfected with 
control siRNA- consistent with our earlier findings - simvastatin had no effect on the FOXO3a-
knockdown cells (Figure 7E). Similarly, knockdown of FOXO3a resulted in increased 
migration of SUM149 cells, and the treatment of these cells with simvastatin was unable to 
inhibit migration (Figure 7F). These results suggest that not only does FOXO3a regulate 
migration and self-renewal, but that simvastatin inhibition is mediated through regulation of 
FOXO3a.  
 
 
 
 
 Figure 7. FOXO3a is a mediator of mammosphere and migration in TNBC cells.
Western blot assay to identify the overexpression efficiency of the plasmids for FOXO3a in 
SUM159 cells. (B) Mammosphere formation presented as the average number of spheres per 
40,000 cells plated relative to the control plasmid ± SD; representative data are shown.  
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 (A) 
 
 Figure 7. FOXO3a is a mediator of mammosphere and migration in TNBC cells.
Representative images of the Transwell assays (magnification, ×40). Quantification of t
numbers of migrating cells relative to the control plasmid is presented as mean ± SD.
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 Figure 7. FOXO3a is a mediator of mammosphere and migration in TNBC cells
Immunoblot with anti-FOXO3a antibodies in SUM149 cells transfected with either siRNA 
targeting FOXO3a or scrambled control siRNA for 48 hours. Beta
control. (E) SUM149 cells transfected with either siFOXO3a or scrambled siControl exposed 
simvastatin (2.5 µM) treatment (24 h) and seeded in self
conditions. Mammosphere formation presented as the average number of spheres per 40,000 
cells plated ± SEM; representative data are shown.
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 Figure 7. FOXO3a is a mediator of mammosphere and migration in TNBC cells.
SUM149 cells transfected with either siFOXO3a or scrambled siControl migrated through an 8 
µm pore in the presence of 2.5 µM simvastatin or vehicle (DMSO). The number of cells that 
passed through the transwell membrane was counted. Significant differences are shown as 
follows: *, P < 0.05 for unpaired 2
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FOXO3a Levels Are Increased in Mouse Xenograft Primary Tumors Treated with 
Simvastatin 
To confirm whether FOXO3a expression is correlated to simvastatin exposure, we tested 
FOXO3a protein expression with immunofluorescence in primary mouse tumors obtained from 
the orthotopic transplantation experiment described earlier. We found the expression of 
FOXO3a was lower in the vehicle pre-treated cells consistent with their increased rate of 
metastases. In the simvastatin treated tumors, the expression of FOXO3a was higher and as 
described these mice developed fewer distant metastases following tumor resection (Figure 8). 
This result suggests FOXO3a has a role in breast cancer metastasis and that simvastatin 
treatment could be a potential therapeutic therapy for preventing breast cancer metastasis.  
 
FOXO3a Predicts For Distant Metastasis Free Survival in Breast Cancer Patients  
To determine whether FOXO3a expression correlates with prognosis in patients with 
breast cancer, we analyzed FOXO3A mRNA expression in 8 public gene expression data sets, 
including 1,479 breast cancers clinically annotated. FOXO3A expression was heterogeneous 
with a range of intensities over 11 units in log2 scale: 759 tumors (51%) showed downregulation 
when compared to normal breast (“FOXO3A-down” group), and 720 (49%) did not (“FOXO3A-
no down” group). We searched for correlations between FOXO3A expression status (down- 
versus no down- groups) and clinicopathological variables (Table 5). No correlation was found 
with patients’ age, grade, pN, pT, and PR status, whereas FOXO3A downregulation was 
associated with ductal type, ER-positive status and ERBB2-negative status (Fisher’s exact test). 
Regarding survival, 1,069 patients remained metastasis-free during a median follow-up of 93 
months (range, 1 to 299) and 410 displayed metastatic relapse. The 5-year MFS rate was 77% 
[95CI, 0.75-0.79]. In univariate analysis (Table 6), axillary lymph node involvement, large 
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tumor size, high grade, ER-negative status, PR-negative status, and ERBB2-positive status were 
associated with poor MFS, as was the FOXO3A-down group (p=0.028, Wald test; HR=1.24 
[1.02-1.51], and p=0.028, log-rank test, Figure 9). In multivariate analysis (Table 6), all these 
features, except ER status, remained associated with poor MFS, including the FOXO3A-down 
group (p=0.024, Wald test; HR=1.29 [1.03-1.60]). The MFS analysis was done in each 
molecular subtype separately. As shown in Figure 9, FOXO3A expression influenced MFS in 
the TN subtype and the HR+/ERBB2- subtype, but not in the ERBB2+ subtype. These results 
suggest that FOXO3a may have a prognostic value for breast cancer metastasis, which is 
consistent with our mechanistic findings. 
 
 
 
 
 
 
 
 Figure 8. FOXO3a correlates with metastasis 
xenografts and bioluminescence imaging of mice injected orthotopically with vehicle
simvastatin treated SUM149 cells. Xenografts were stained with an anti
(Green) and DAPI (Blue). Images are at 100X magnification. 
obtained after 8 weeks following primary xenograft resection. Mice were injected with D
Luciferin and imaged in an IVIS NOVIS Lumina imager. 
 
 
 
 
 
48 
in vivo. Immunofluorescence 
-FOXO3a antibody 
Bioluminescence imaging was 
 
 
images of primary 
-DMSO or 
-
49 
 
 
Table 5: Correlations of FOXO3A expression with clinicopathological characteristics in breast 
cancer. 
 
 
 
 
 
 
 
 
 
no down
(N=720)
down
(N=759)
Age, years 0.467
<=50 657 322 (57%) 335 (60%)
>50 463 238 (42%) 225 (40%)
Pathological type 1.43E-02
IDC 376 196 (74%) 180 (84%)
ILC 35 25 (9%) 10 (5%)
MIX 21 10 (4%) 11 (5%)
other 48 34 (13%) 14 (7%)
Pathological grade 0.424
1 279 142 (20%) 137 (19%)
2-3 1158 557 (80%) 601 (81%)
Pathological axillary lymph node status, pN 0.381
negative 866 432 (67%) 434 (65%)
positive 443 209 (33%) 234 (35%)
Pathological tumor size, pT 0.955
pT1 607 301 (48%) 306 (48%)
pT2-3 653 322 (52%) 331 (52%)
ER status 4.18E-03
negative 403 221 (31%) 182 (24%)
positive 1076 499 (69%) 577 (76%)
PR status 0.599
negative 632 313 (43%) 319 (42%)
positive 847 407 (57%) 440 (58%)
ERBB2 status 1.34E-02
negative 1313 624 (87%) 689 (91%)
positive 166 96 (13%) 70 (9%)
5-year MFS [95CI] 1479 80 [0.77-0.83] 74 [0.71-0.77] 2.79E-02
Characteristics*
FOXO3A
 expression-based groups
p-valueN
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Table 6: Univariate and multivariate analyses for MFS in breast cancer  
 
 
 
N HR [95CI] p-value N HR [95CI] p-value
FOXO3A expression-based group down vs. no down 1479 1.24 [1.02-1.51] 2.82E-02 1228 1.29 [1.03-1.6] 2.40E-02
Age, years >50 vs. <= 50 1120 0.97 [0.77-1.21] 0.76
Pathological type ILC vs. IDC 480 1.30 [0.74-2.27] 0.213
MIX vs. IDC 0.66 [0.27-1.63]
other vs. IDC 0.53 [0.25-1.15]
Pathological grade 2-3 vs. 1 1437 2.89 [2.06-4.06] 7.56E-10 1228 2.08 [1.45-2.99] 6.42E-05
Pathological axillary lymph node status, pN positive vs. negative 1309 1.63 [1.32-2.01] 5.29E-06 1228 1.35 [1.08-1.70] 9.87E-03
Pathological tumor size, pT pT2-3 vs. pT1 1260 1.64 [1.32-2.04] 8.81E-06 1228 1.41 [1.12-1.77] 3.12E-03
ER status positive vs. negative 1479 0.58 [0.47-0.71] 1.11E-07 1228 0.88 [0.67-1.17] 0.40
PR status positive vs. negative 1479 0.57 [0.47-0.69] 8.40E-09 1228 0.70 [0.54-0.91] 7.26E-03
ERBB2 status positive vs. negative 1479 1.58 [1.20-2.08] 1.04E-03 1228 1.37 [1.01-1.86] 4.51E-02
Univariate MultivariateCharacteristics
 Figure 9. High FOXO3a mRNA levels are associated with better clinical outcome
metastatic patients. Kaplan-
associated with longer metastasis free survival
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2.5 Discussion  
Our results show that TNBC cells pre-exposed to simvastatin had less metastasis-
associated in vitro characteristics and formed less metastasis in vivo, and that reduction of 
metastasis in vivo after simvastatin pre-treatment was correlated with intact FOXO3a signaling. 
We further showed that FOXO3a mRNA expression levels are positively correlated with 
patients’ distant-metastasis-free survival.  
 In the  current proposed clinical model, the use of statins is for primary tumor 
prevention and treatment 79, but our study suggests simvastatin should be further considered for 
metastasis prevention. The anti-tumor effects of statins were observed over 20 years ago 80,81. 
Subsequent research confirmed statins inhibit breast cancer proliferation in vitro and tumor 
growth in vivo 82-86. The association between statin use in patients and breast cancer incidence 
has not been as clear. Undela et al. investigated the relationship of statin use and breast cancer 
risk in 24 observational studies, reporting data from more than 2.4 million participants, 
including 76,759 breast cancer cases. Their findings showed no association of statin use with 
reduced risk of breast cancer 87. To move forward with any clinical trials of the efficacy of 
statins in treating metastasis, biomarkers are necessary to separate patients into groups that 
would be predicted to be responsive to the effects of the drug.  
FOXO3a has been previously described as a tumor suppressor in various tumors, 
including breast cancer, and is regulated by Akt, a pathway commonly deregulated in breast 
cancer 78. FoxO3 acts as a transcription factor and triggers apoptosis through induction of death 
genes such as FasL and Bim1 88.  Ni et al showed that FOXO3a silencing promoted invasiveness 
of renal cancer cells and metastasis of renal cancer cells in vivo 89.  Furthermore, Gopinath et al 
demonstrated a functional requirement for FOXO3a as a regulator of the Notch signaling 
pathway, a pathway critical for the self-renewal and maintenance of CSCs 90. Our data further 
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showed that FOXO3a mRNA levels were a significant predictor of distant-metastasis-free 
survival in breast cancer patients implying FOXO3a could be useful as a marker for metastatic 
outcomes in breast cancer patients. A recent study by Jiang and colleagues showed high 
expression level of FOXO3a was significantly correlated with long-term survival 91. Whether it 
may be predictive of response to statin therapy remains to be examined. Our data showed that 
FOXO3a-knockdown cells were resistant to simvastatin treatment. The results of our study 
suggest a model wherein simvastatin treatment leads to increased activity of FOXO3a and 
finally inhibition of metastasis (Figure 6). Our observation that simvastatin decreased the rate 
of G1-to-S-phase progression is consistent with previous studies showing statins increase the 
expression of cell cycle inhibitors ,which have been shown to decrease the self-renewal capacity 
of CSCs 92-94. FOXO3a also mediates decreased transcription of CDKN1B 95, and therefore the 
increased activity of FOXO3a through simvastatin treatment could be the mechanism 
underlying the cell cycle arrest that we observed. This inhibition of the G1-to-S-phase transition 
could be the mechanism underlying the decreased CSC self-renewal capacity observed in our 
study. 
Our data are consistent with data from previous statin studies showing that statins can 
inhibit self-renewal capacity. Ginestier et al showed that simvastatin targeted CSCs through 
RhoA/CDKN1B signaling 32. Similarly, Ni et al. observed downregulation of FOXO3a 
increased metastasis and predicted worse metastasis-free survival in patients with renal cell 
carcinoma 89. This paper distinguishes itself from Ginestier et al because they looked at tumor 
initiation and this study focused on metastasis initiation. This study’s focus was not on a 
treatment of metastasis and as such these results suggest statins could be used for preventing 
metastasis. Consistent with the clinical data in IBC showing it only helps in stage III, i.e. too 
late in those who develop metastasis in spite of statins 65. 
54 
 
 The major strengths of this study are the use of two in vivo assays to study metastasis 
formation and the use of a large-scale screening tool in RPPA. Our study also has limitations. 
We pretreated cells before injection; therefore, we do not know how long the effects of 
simvastatin lasted once the cells were injected in vivo.  Future studies involving treatment of 
mice with daily simvastatin and measurement of metastasis are warranted. The mammosphere 
and Aldefluor assays both measure tumor initiation capacity but are only surrogates for CSC 
likeness. To more effectively study simvastatin’s effect on CSCs, additional studies using in 
vivo serial dilutions are warranted.  
 
2.6 Conclusions 
We showed that simvastatin inhibits breast cancer cells’ ability to form metastases in 
spontaneous and experimental metastasis models. Furthermore, for the first time, we showed 
that FOXO3a in breast cancer is regulated by simvastatin and that FOXO3a mRNA expression 
levels in breast cancer patients correlated with distant-metastasis-free survival. Our findings 
underscore the potential of statins for breast cancer therapy. 
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Chapter III 
High-density lipoprotein and very-low-density lipoprotein have opposing roles in 
regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer 
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This chapter is based upon the journal article “High-Density and Very-Low-Density 
Lipoprotein Have Opposing Roles in Regulating Tumor-Initiating Cells and Sensitivity to 
Radiation in Inflammatory Breast Cancer. Wolfe, A.R., R.L. Atkinson, J.P. Reddy, B.G. 
Debeb, R. Larson, L. Li, H. Masuda, T. Brewer, B.J. Atkinson, A. Brewster, N.T. Ueno, 
and W.A. Woodward, International Journal of Radiation Oncology*Biology*Physics, 
2015. 91(5): p. 1072-1080.” It was approved by the publisher for reuse in this thesis.  
3.1 Abstract 
Purpose: We previously demonstrated that cholesterol-lowering agents regulate radiosensitivity 
of inflammatory breast cancer (IBC) cell lines in vitro and are associated with less 
radioresistance among IBC patients who undergo postmastectomy radiation.  We hypothesized 
decreasing IBC cellular cholesterol induced by treatment with lipoproteins increases radiation 
sensitivity. Here, we examined the impact of specific transporters of cholesterol (i.e., 
lipoproteins) on the responses of IBC cells to self-renewal and to radiation in vitro and on 
clinical outcomes in IBC patients. 
Methods and Materials: Two patient-derived IBC cell lines, SUM 149 and KPL4, were 
incubated with low-density, very-low-density, or high-density lipoproteins (LDL, VLDL, or 
HDL) for 24 hours prior to irradiation (0-6 Gy) and mammosphere formation assay. Cholesterol 
panels were examined in a cohort of patients with primary IBC diagnosed between 1995 and 
2011 at XXX. Lipoprotein levels were then correlated to patient outcome using the log rank 
statistical model and examined in multivariate analysis using Cox regression.  
Results: VLDL increased and HDL decreased mammosphere formation compared to untreated 
SUM 149 and KPL4 cells. Survival curves showed enhancement of survival in both IBC cell 
lines when pretreated with VLDL, and conversely radiosensitization in all cell lines when 
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pretreated with HDL. In IBC patients, higher VLDL values (>30 mg/dL) predicted a lower 5-
year overall survival rate than normal levels (HR [95% CI] = 1.9 [1.05-3.45], P= 0.035). Lower 
than normal patient HDL values (<60 mg/dL) predicted a lower 5-year overall survival rate than 
values higher than 60 mg/dL (HR [95% CI] = 3.21 [1.25-8.27], P=0.015). 
Conclusions: This study discovered a relationship between the plasma levels of lipoproteins, 
overall patient response, and radioresistance in IBC patients and IBC patient-derived cell lines. 
A more expansive study is needed to verify these observations." 
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3.2 Introduction 
Inflammatory breast cancer (IBC) comprises approximately 5% of all breast cancer cases 
and is a rare, phenotypically distinct, highly aggressive form of locally advanced breast 
cancer.11 IBC is highly invasive and has a high propensity to invade into the dermal lymphatics 
and metastasize to distant organs.96 These features confer to IBC an extremely high metastatic 
potential, which accounts for its poor prognosis: the 5-year overall survival (OS) rate is only 
40.5%.97 Even with dose escalation and modified treatment regimens, local recurrence rates 
after radiation remain high, and morbidity due to local failure is significant. In the search for 
methods to sensitize IBC tumors to conventional therapies, the plasticity of IBC tumor cells has 
been extensively studied.98  
IBC is enriched in gene signatures identified in tumor initiating cells (TICs), TICs have 
been defined several ways but most conservatively are prospectively identified cells that self-
renew to initiate tumors in transplantation assays. Enrichment for gene expression found in TICs 
may contribute to IBC resistance to standard therapies.98 TICs have been shown to be important 
in resistance to therapies such as radiation and chemotherapy,99-101 and new strategies for 
advanced cancer therapies increasingly include TIC-targeting drugs. Studies have shown cells 
that share markers with TICs have an enhancement in DNA repair including increases in CHK1, 
CHK2, and RAD51.102,103  
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase, or statins, 
have been shown to increase self-renewal of tumor cells via inactivation of Ras homolog family 
member A and increased accumulation of P27kip1 in the nucleus.32 Interestingly, in a 
retrospective analysis of 723 IBC patients from MD Anderson Cancer Center, treatment with a 
hydrophilic statin was associated with significantly longer progression-free survival (PFS) than 
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no statin.33 Statins are known to regulate concentrations of lipoproteins in the blood, and the 
lipoproteins—low-density lipoprotein (LDL), high-density lipoprotein (HDL), and very-low-
density lipoprotein (VLDL)—mediate cholesterol homeostasis in the blood.104 Martin and van 
Golen recently demonstrated that IBC cells display differences in uptake and storage of 
cholesterol compared to non-IBC cells. IBC cells were able to maintain intracellular stores of 
cholesterol in cholesterol-depleted environments, while non-IBC cells could not.22 Even though 
statins are known to decrease the “bad” cholesterol, LDL and VLDL, and increase “good” 
cholesterol, HDL,79,105 the effects of regulating these lipoproteins was never established at the 
cellular level. Furthermore, the role of specific cholesterol transport lipoproteins on TIC 
survival and radiosensitivity in IBC cell lines has not been reported. 
We hypothesized altering IBC cellular cholesterol induced by treatment with 
lipoproteins increased radiation sensitivity. Here, we examined the impact of specific 
transporters of cholesterol (i.e., lipoproteins) using in vitro assays of self-renewal and 
radioresistance of IBC cells and on clinical outcomes in IBC patients. Together, our analyses of 
patient outcomes and preclinical data specifically demonstrates that radiosensitization of IBC by 
statins was due to changes in HDL and VLDL levels, and that dyslipidemia (i.e., clinically low 
HDL and high VLDL) was associated with worse outcomes among IBC patients. 
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3.3 Methods and Materials 
Cell culture and reagents 
The SUM 149 IBC cell line is commercially available (Asterand, Detroit, MI). Cells were 
incubated in normal cell culture conditions
 
with Hams–F12 cell culture medium supplemented 
with
 
1 µg/mL hydrocortisone, 5 µg/mL insulin, and 1% antibiotic-antimycotic. The KPL4 IBC 
cell line was maintained in DMEM/F-12 medium supplemented with 10% fetal bovine serum. 
Lipoproteins VLDL, LDL, and HDL were purchased from Sigma-Aldrich (St. Louis, MO).  For 
all experiments including lipoproteins, serum was not added to the media to remove the 
cholesterol and lipoprotein contained in fetal bovine serum. 
Mammosphere formation assay 
To generate primary mammospheres, cells in monolayer culture, pretreated with lipoproteins for 
24 hours or untreated, were grown in standard mammosphere medium (serum free, growth 
factor enriched). Low-attachment plates were used, as described previously [16]. For secondary 
mammosphere assay, cells from primary mammospheres were dispersed with 0.05% trypsin, 
seeded in ultra-low-attachment plates (20,000 cells/mL) in mammosphere medium, incubated 
for 7 days, and counted. All 3 lipoproteins were used at a concentration of 10 µg/mL in all in 
vitro experiments to simulate normal cholesterol lipoprotein levels found in human blood 
samples.  
Clonogenic survival assays 
Clonogenic viability of the SUM 149 and KPL4 cells was tested in triplicate in both standard 
monolayer conditions (referred to here as 2D culture) and 3D culture conditions. Cells in 2D 
culture were incubated for 14 days after treatment with VLDL, LDL, or HDL and irradiation. 
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Crystal violet staining (10%) was used to mark colonies with 50 cells or more (≥300 µm 
diameter). Survival curves were obtained for all groups and curves were fitted on the basis of 
the linear-quadratic model. 
Delivery of radiation 
Cell lines were grown to 75% confluence and lipoproteins were added to the cell culture 
medium 24 hours prior to irradiation. Cells were irradiated using a 137Cs source (Shepherd 
Irradiator, J.L. Sheperd and Associates, San Fernando, CA). Cells were washed twice with 
phosphate-buffered saline solution (PBS) and plated for 2D culture; 14 days later, colonies were 
stained with crystal violet. For 3D culture, cells were plated for 7 days immediately following 
irradiation. Spheres with a minimal size of 50 µM were counted using a Gelcount colony 
counter (Oxford Optronix, Oxford, UK). 
Cholesterol staining 
SUM 149 cells were incubated with HDL or VLDL for 24 hours and fixed and stained with 
cholesterol-specific stain filipin III (Abcam Cholesterol Kit Catalog # ab133116), a bacterial by-
product that fluoresces after interacting with an isomer of cholesterol. Image J software was 
used to quantify the mean fluorescence for a sample of 6 images.  
Immunoblotting 
Western blot analysis was performed with precast gradient gels (Novex Life Technologies) 
using standard methods. Briefly, cells were lysed in the RIPA buffer containing protease 
inhibitors and phosphatase inhibitors (Sigma). Membranes were probed with the specific 
primary antibodies, followed by peroxidase-conjugated secondary antibodies. The following 
62 
 
antibodies were used: antibodies against pEGFR, EGFR, Akt, pAkt, FOXO3a, and pFOXO3a 
(Cell Signaling). 
Immunofluorescence  
Following irradiation at time points of 30 min, 4 hours, and 24 hours, cells were cultured in 
chamber slides overnight and fixed with 4% formaldehyde in PBS for 30 min, followed by 
permeabilization with 0.1% Triton X-100 in PBS for 1h. Cells were then blocked for 
nonspecific binding with 1% BSA in for 1h, and incubated with the γH2AX antibody (1:400, 
Cell Signaling) overnight at 4°C.  Alexa Fluor 488 goat anti-rabbit IgG (1:400, Cell Signaling) 
for 1 h at RT. Coverslips were mounted on slides using anti-fade mounting medium with DAPI 
(Cell Signaling).  
Patient data 
Patient and tumor characteristics for women with stage III or stage IV primary IBC diagnosed 
between January 12, 1995, and January 27, 2011, at MD Anderson Cancer Center were reported 
previously under a protocol approved by the MD Anderson Cancer Center Institutional Review 
Board [11]. Data on lipid and cholesterol levels were available for 193 of the women in this 
cohort and were extracted from the laboratory results database. These data were merged into the 
patient/tumor data, which included statin use, and these 193 patients comprised the cohort 
examined in this analysis.  
Statistical analysis 
For in vitro studies, statistical significance was determined by using the Student t-test, 
calculated by Origin software. For patient data, associations between categorical variables were 
assessed via cross-tabulation and the Χ2-test or Fisher exact test, where appropriate. Five-year 
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OS was estimated by using the Kaplan-Meier method. Both univariate and multivariate Cox 
proportional hazard models were applied to assess the effect of covariates of interest on OS. 
 
3.4 Results 
In vitro lipoprotein treatment of IBC cells results in changes in self-renewal and 
radiosensitivity. 
We determined the effects of treatment with lipoproteins on the capacity of IBC cells to 
form secondary mammospheres in 3D culture conditions. Secondary mammosphere forming 
efficiency is an in vitro assay of self-renewal, a critical attribute of stem-like cells. VLDL 
significantly increased primary and secondary mammosphere forming efficiency (MSFE) in 
both SUM 149 and KPL4 cells compared to untreated cells (Figure 10). In SUM 149 cells, the 
effect of VLDL on secondary mammosphere formation was slightly greater than that on primary 
mammosphere formation (50% vs. 33% enhancement; P<0.05). For KPL4 cells, primary and 
secondary mammosphere formation was enhanced 42% by VLDL treatment. Conversely, HDL 
treatment significantly reduced the number of mammospheres formed compared to untreated 
cells in both cell lines: mammosphere formation by SUM 149 cells was reduced by 21% and 
mammosphere formation by KPL4 cells was reduced by 70% (Fig. 10; P<0.05). LDL treatment, 
on the other hand, was associated with no significant difference in mammosphere formation 
compared to untreated IBC cells (Figure 10). These findings suggest that VLDL increases and 
HDL decreases self-renewing cells that survive in low attachment, serum free conditions.  
  
 
 Figure 10. The impact of lipoproteins on mammos
3D culture. (A). SUM 149 (left) and KPL4 cells (right) were treated with LDL, HDL, or VLDL 
(10 µg/mL) and incubated for 24 hours to evaluate mammosphere formation (* P<0.05 in 
triplicate independent experiments). 
mammospheres in culture. VLDL was observed to increase growth of primary and secondary 
mammospheres, and HDL to inhibit this growth. 
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phere formation was demonstrated in 
(B) Light-microscope images (40×) of the primary 
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In light of the radiation resistance of cells capable of growing as mammospheres and our 
previous work demonstrating statin treatment radiosensitizes mammospheres,65 we investigated 
the effect of lipoprotein treatments on radiosensitivity of IBC cells. Clonogenic assays were 
performed with SUM 149 and KPL4 cells treated in the same conditions as for the 
mammosphere formation assay (10 µg/mL of VLDL, HDL, or LDL). After 24 hours of 
lipoprotein treatment, cells were irradiated with increasing doses of radiation between 0-6 Gy 
and then seeded in 2D or 3D culture conditions (Figure 11). Consistent with the findings on 
mammosphere-forming efficiency, VLDL increased radioresistance and HDL enhanced 
radiosensitivity of both IBC cell lines. These findings led us to hypothesize that 
radiosensitization of IBC could be due to the increased and decreased cellular levels of 
cholesterol induced by VLDL and HDL, respectively. 
Decreased IBC cellular cholesterol concentrations correlate with decreased growth factor 
signaling and increased DNA repair following radiation 
To elucidate the role of cholesterol transport in the response to radiation, we sampled 
cells from the clonogenic assays treated with VLDL or HDL to image intracellular levels of 
cholesterol before irradiation. VLDL-treated cells showed a 1.3-fold increase in cholesterol 
content in the intracellular environment (P=.03), while cells treated with HDL showed a 3-fold 
decrease in intracellular cholesterol content (P<.01) (Figure 12).To explore the mechanistic 
connection between lipoprotein treatment and response to radiation we examined reverse phase 
protein array (RPPA) data from statin treated breast cancer cells (Chapter 2) and observed Akt 
and FOXO3a to be regulated by statins. In addition Van Laere et al have previously shown 
higher (Akt) and lower (FOXO3a) expression in IBC patients compared to non-IBC.98  
 
 Figure 11. The effect of lipoprotein treatment on radiation response of SUM 149 and 
KPL4 cells. (A). We observed in 2D cultures that VLDL caused radioprotection, HDL 
radiosensitized, and LDL showed no effect on radi
The same effects were observed in mammosphere 3D culture. Left panels represent SUM 149 
and right panels KPL4.  
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ation response in both IBC cell lines. 
 
(B). 
 Figure 12. In vitro detection of cholesterol levels in SUM 149 cells by filipin staining
Leica microscopy images (40
treatment with VLDL, HDL, or a combination. 
activity is shown.  
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AKT and FOXO3A signaling is a key cytoprotective response in many cell types downstream of 
the EGFR family receptor.106,107 SUM 149 (Figure 13A) and KPL4 cells (Figure 13B) treated 
with HDL or VLDL 24 hours prior to EGF (15 ng/mL) stimulation displayed lower (HDL) and 
higher (VLDL) protein ratios of pEGFR:EGFR, pAKT:Akt, and pFOXO3a:FOXO3a compared 
with control SUM 149 and KPL4 cells. 
Gamma-H2AX (γH2AX) is a marker for DNA double strand repair after ionizing 
radiation treatment and γH2AX foci persist longer in radiosensitive cell lines than in 
radioresistant lines.108 We observed persistence (HDL treated) and decreased (VLDL treated) γ
H2AX foci at 4 hours after 4 Gy ionizing radiation treatment (HDL, 4.27 fold increase P=.001, 
VLDL, 0.15 fold decrease P=.009) and continued differences at 24 hours (HDL, 5.5 fold 
increase P=.001, VLDL, 0.1 fold decrease P=.005) (Figure 13C), indicating HDL treated IBC 
cells were less able to repair DNA lesions and VLDL treated IBC cells were better able to repair 
DNA lesions. It is important to highlight, HDL treated SUM 149 cells had higher baseline γ
H2AX foci starting at 0.5 hours following irradiation (1.8 fold increase, P=.002), while VLDL 
treated SUM 149 showed similar γH2AX foci (0.8 fold decrease P=0.27) after 0.5 hours.   
Dyslipidemia in IBC patients predicts overall survival 
To expand the relevance of this work to patients, we correlated lipoprotein levels to OS 
in the cohort of 193 patients with stage III or stage IV IBC. Their lipid and cholesterol panels 
were analyzed; patients with stage III or IV disease were analyzed together as there was no 
significant difference by stage (P = 0.1). A summary of patient characteristics is presented in 
Table 7. Lipid panels were drawn per physician preference and practice and presumably 
represent a bias toward women with known dyslipidemia or risk factors for dyslipidemia. 
 Figure 13. HDL and VLDL have opposite effects on FOXO3a phosphorylation
Damage Response. (A) Immunoblotting of pEGFR, pAKT, pFOXO3a, and Actin in SUM 149 
and (B). KPL4 cells treated with either HDL or VLDL for 24 h. 
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 and DNA 
 Figure 13. HDL and VLDL have opposite effects on FOXO3a phosphoryl
Damage Response. (C). γH2AX and DAPI staining of SUM 149 and KPL4 cells treated with 
either HDL or VLDL, .5h, 4 h,
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 and 24 hours after 4 Gy ionizing radiation. Images at 100X.
 
ation and DNA 
 
 Table 7. Patient Characteristics 
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The demographic and clinical characteristics of this subset of 193 women were similar to 
those of the larger cohort.33 The women were older (78% older than 45 years), demonstrated 
high body mass index (48% BMI >30), and were predominantly postmenopausal (60.6%). 
Approximately 20% of the patients had triple-negative disease, and the majority of patients 
received radiation therapy (75%). The patients had higher than normal LDL (>100 mg/dL, 63%) 
and VLDL (>30 mg/dL, 38%) levels and lower than normal HDL levels (<60 mg/dL, 73%). 
Statin users comprised 24% of the total number. Statin users had significantly better 
locoregional control of disease (82% vs. 54%, P = 0.003). No local failures occurred among 
statin users during the 36 months after treatment. Patients with an HDL level higher than 30 
mg/dL had a significantly higher 5-year local/regional recurrence-free survival rate than patients 
with an HDL level less than 30 mg/dL (98% vs. 74% respectively, P=0.003) Kaplan Meier 
curves for 5 year OS and local/regional recurrence-free survival by baseline HDL levels are 
shown in Figure 14.  
 The risk factors that were included in the multivariate model (P<0.25 in univariate 
analysis) were ER status (P=0.02), PR status (P=0.04), HER2 status (P=0.11), triple-negative 
status (P<0.0006), total cholesterol level (P=0.11), HDL level (P=0.03), VLDL level (P=0.06), 
statin use (P=0.23), and menopausal status (P=0.13) (Table 8). In the final multi-covariant Cox 
model, triple-negative breast cancer, HDL, and VLDL were significant predictors of 5-year OS 
(Table 9). Patients with a higher than normal VLDL level had a significantly lower 5-year OS 
rate than patients with a normal VLDL level (HR [95% CI] = 1.9 [1.05-3.45], P= 0.035). 
Similarly, patients with a lower than normal HDL level had a significantly lower 5-year OS rate 
than patients with a normal HDL level (HR [95% CI] = 3.21 [1.25-8.27], P=0.015). Of the 72 
patients who had died by January 27, 2011, 68 died of disease. Of the other 4 patients, 3 were in 
the no statin group; one died of a fall, one of metastatic endometrial cancer, and one of  
 Figure 14. Kaplan Meir Curves for HDL outcomes. (
survival curve comparing patients with high HDL level (>30 mg/dL) and those with low HDL 
level (<30 mg/dL; P=0.004). 
abnormal serum HDL levels determined from blood samples collected at the time of IBC 
diagnosis. 
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A). Locoregional recurrence
(B). Overall survival curves comparing patients with normal vs. 
-free 
 Table 8. Univariate analysis of all patients.
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unknown cause. Removing stage IV, the LRR and OS remain significant for high HDL vs not, 
97 vs 68% LRR, P = .004, 84% vs 59%, P = .015. The trend remains for OS in stage IV patients 
but is not significant suggesting using the entire cohort makes the results more conservative 
rather than biasing them. 
 
3.5 Discussion 
In this study we demonstrated that lipoproteins VLDL and HDL had opposite effects on 
IBC cells grown as mammospheres and on these cells’ radioresistance in vitro, and the level of 
both lipoproteins predicted 5-year OS in IBC patients. 
  Previous studies have shown that cholesterol and lipoproteins LDL and VLDL are 
significantly elevated in breast cancer patients compared to controls.35 In addition, 
hypercholesterolemia was discovered to be an independent risk factor for breast cancer in 
postmenopausal women.109-111 The cholesterol metabolite 27-hydroxycholesterol increased ER-
positive breast tumor growth in vivo through a liver X receptor agonist mechanism.21 
Furthermore, mice fed a high cholesterol diet developed more aggressive tumors and had 
significantly more metastasis in a breast cancer model.20 We have previously shown statins, 
which inhibit de novo cholesterol synthesis, were shown to radiosensitize inflammatory breast 
cancer cells in vitro.65 Herein we observed in vitro, intracellular levels of cholesterol in IBC 
cells are altered by HDL and VLDL treatment, ultimately modifying response to radiation by 
reducing (HDL) or increasing (VLDL) self-renewal of these cells, as shown by our 
mammosphere-forming assay. Importantly, a clinical correlation between HDL and local control 
after post-mastectomy radiation is identified. Of course independent validation is critical and it 
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remains to be seen if this effect is limited to IBC as might be predicted by the in vitro work by 
Martin and van Golen showing unique cholesterol properties in IBC cells.22  
Cholesterol plays an important role in cell membrane integrity and fluidity.112 Several 
growth factor signaling receptors are located in cholesterol rich domains in the membrane and  
RPPA analysis of statin treated and untreated cells suggested signaling downstream of EGFR 
were regulated by statins. Interestingly, EGFR is well described to be activated by association 
with cholesterol mediated lipid rafts in the membrane.113,114 We examined these as potentially 
regulated signals in direct lipoprotein treatments HDL inhibited phosphorylation of EGFR, Akt, 
and FOXO3a and VLDL was observed to increase these phosphorylated levels. Phosphorylated 
Akt is downstream of EGFR and has been shown to be important in radiation resistance.115-117 
FOXO3a is a tumor suppressor, inactivated by phosphorylation, which increases cell death 
following DNA damage from radiation.118 We showed DNA damage repair was decreased with 
HDL treatment and increased in VLDL treatment following radiation (Figure 13). We speculate 
that cholesterol enriched IBC membranes promote EGFR signaling through lipid raft formation 
and that HDL can directly reduce lipid raft mediated signaling by removing cholesterol from the 
membrane.  
3.6 Conclusions 
Our results demonstrate a potential role for dyslipidemia in radiation sensitivity and 
survival among IBC patients. We also highlight the urgent need for further studies on the 
potential benefit of aggressively correcting dyslipidemia in IBC patients at the time of diagnosis 
and the role of altering lipid profiles in IBC patients without clinical dyslipidemia.  
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Chapter IV 
MiR-33a Regulates Radiation Sensitivity to High Density Lipoprotein in Breast Cancer 
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4.1 Abstract  
Purpose: We previously showed that high-density lipoprotein (HDL) radiosensitizes 
inflammatory breast cancer (IBC) cells in vitro (chapter 3). Since the microRNA miR-33 family 
controls expression of ABCA1, a cellular transporter of cholesterol efflux to HDL, we 
hypothesized that differences in miR-33a expression in breast cancer cell lines correlates with 
their radiation sensitivity following exposure to HDL in vitro.  
Materials and Methods: miR-33a expression was analyzed by reverse transcriptase–
polymerase chain reaction in five cell lines representing common clinical breast cancer 
subtypes. Cell lysates were subjected to western blot analysis for ABCA1 expression. 
Clonogenic survival in vitro was determined following overexpression or knockdown of miR-33 
via transfection of miR-33a mimic or anti-miR-33a constructs, respectively. The radiosensitivity 
of the breast cancer cell lines was quantified at baseline and following HDL treatment. Kaplan-
Meier analysis determined the clinical impact of miR-33a expression on distant relapse-free 
survival (DRFS) of 210 cases downloaded from the Oxford breast cancer dataset. 
Results: Expression levels of miR-33a varied among the five breast cancer cell lines. 
Clonogenic survival following 24 hours of HDL treatment was decreased in response to 
irradiation in the low miR-33a–expressing cell lines, SUM 149 and KPL4, but survival 
following HDL treatment did not change in the high miR-33a–expressing cell lines, MDA-MB-
231 and SUM 159. In the high miR-33a–expressing cell lines, anti-miR-33a transfection 
decreased cell survival. Conversely, in the low miR-33a–expressing cell lines, miR-33a mimic 
reversed the HDL-induced radiosensitization observed previously. Breast cancer patients in the 
top quartile of miR-33a expression had markedly lower rates of DRFS than the bottom quartile 
(p= 0.0228, log-rank test). 
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Conclusions:  Our results reveal miR-33a regulates HDL-induced radiation sensitivity in breast 
cancer.  
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4.2 Introduction 
 The majority of breast cancer patients receive radiation therapy because of its efficacy in 
reducing local recurrence.119 We do not yet have biological markers that accurately identify 
patients with the highest likelihood of recurrence following radiation therapy. Therefore, our 
ability to personalize the decision to administer radiation therapy is limited. Our group has 
found a relationship between outcomes of an aggressive type of breast cancer, inflammatory 
breast cancer (IBC), and cholesterol regulation, including local recurrence after radiation 
therapy and overall survival. A previous study showed that IBC patients taking a statin (a drug 
that lowers serum cholesterol level) had lower local recurrence rates following radiation therapy 
than patients not taking a statin, and preclinical studies showed that statins radiosensitized both 
IBC and non-IBC cells.65 A follow-up study looked at the same patient cohort to determine if 
lipoproteins (which transport serum cholesterol) also predicted patient outcome. IBC patients 
with a higher than normal level of high-density lipoprotein (HDL, which transports cholesterol 
from peripheral tissues to the liver), had longer overall survival than patients with a lower than 
normal HDL level. In vitro studies showed that treatment of IBC cell lines with HDL led to 
increased radiation sensitivity.120 
 Preclinical studies have supported the role of cholesterol regulation in breast cancer 
progression, mostly in estrogen receptor–positive (ER+) subtypes.20,21,121 The exact mechanism 
by which cholesterol promotes breast cancer progression and radiation resistance is not clearly 
understood. The main mediators of cholesterol efflux from intracellular to extracellular HDL are 
the adenosine triphosphate–binding cassette (ABC) transporters ABCA1 and ABCG1.36 
ABCA1 deficiency in cancer cells was shown to increase cellular cholesterol, leading to 
increased cell survival.122 In prostate cancer, hypermethylation of the ABCA1 promoter, which 
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led to elevated cholesterol levels, was detected in high-grade prostate cancers but not in normal 
prostate tissues.123 
 MicroRNAs (miRNAs) are noncoding small RNAs that repress translation and cleave 
mRNA by binding to the 3′-untranslated region of their target gene.124 MiR-33 is known to 
inhibit the expression of cholesterol transport genes, including ABCA1 and ABCG1.125 MiR-33 
silencing in vivo increased hepatic expression of ABCA1 and plasma HDL levels.37 Additional 
studies showed that miR-33 can promote glioma-initiating cells126 and was upregulated in 
patients with chemoresistant osteosarcoma.127,128 
 The connection between cholesterol transport and radiation sensitivity has not been 
described. We hypothesized that expression of miR-33 regulates HDL-induced breast cancer 
radiosensitivity by inhibiting ABCA1 and ABCG1. We tested our hypothesis by manipulating 
the expression of miR-33 in high and low miR-33–expressing breast cancer cell lines and testing 
their radiation sensitivity in the presence or absence of HDL. Our results indicate that miR-33a 
expression correlates with HDL-induced radiosensitivity in vitro.  
 
4.3 Materials and Methods 
Cell culture and drugs 
Five breast cancer cells lines were chosen to represent a variety of breast cancer subtypes. 
SUM149 (ER-/human epidermal growth factor receptor 2 [HER2]-) and SUM159 (ER-/HER2-) 
cells were obtained from Asterand (Detroit, MI). Both types of cells were cultured in Ham F12 
medium supplemented with 10% fetal bovine serum (FBS), 1 µg/mL hydrocortisone, 5 µg/mL 
insulin, and 1% antibiotic-antimycotic. MDA-231 cells (ER-/HER2-) were obtained from 
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American Type Culture Collection (Manassas, VA) and were cultured in α-media supplemented 
with 10% FBS, 1 µg/mL hydrocortisone, 1 µg/mL insulin, 12.5 ng/mL epidermal growth factor, 
sodium pyruvate, nonessential amino acids, 2 mM glutamine, and 1% antibiotic-antimycotic. 
KPL4 IBC cells (ER-/HER2+) were maintained in DMEM/F-12 medium supplemented with 
10% FBS. MCF-7 (ER+/HER2-) cells were cultured as monolayer in modified Eagle’s medium 
(MEM) supplemented with 10% FBS, 0.1 mM nonessential amino acids, 1 mM sodium 
pyruvate, 5 µg/ml insulin, 1 µg/ml hydrocortisone, and 1% antibiotic-antimycotic. Human HDL 
was purchased from Sigma-Aldrich (St. Louis, MO).  For all experiments including 
lipoproteins, serum was not added to the medium to prevent contamination/confounding of the 
results by the cholesterol and lipoprotein contained in FBS. 
RNA isolation and miRNA PCR 
Total RNA was isolated from the cell lines by using Trizol reagent (Invitrogen, Grand Island, 
NY) according to manufacturer's protocol. To isolate the miRNAs, RNA isolated from cell lines 
was reverse-transcribed to cDNA using the TaqMan MicroRNA Reverse Transcription kit 
(Applied Biosystems, Foster City, CA) following the manufacturer’s instructions and subjected 
to polymerase chain reaction (PCR) in a Thermal Cycler (BioRad, Hercules, CA) at 16°C for 30 
minutes, 42°C for 30 minutes, and 85°C for 5 minutes. The expression levels of mature miR-
200 family members were measured by quantitative reverse-transcription PCR (qRT-PCR) 
using TaqMan MicroRNA assays (Applied Biosystems) according to the manufacturer’s 
instructions. The reaction was performed in a 7300 real-time PCR system (Applied Biosystems) 
at 95°C for 10 minutes and 40 cycles at 95°C for 15 seconds and 60°C for 60 seconds. U6 was 
used as a reference.  
Immunoblotting  
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For immunoblotting, cells were subjected to lysis in 1× RIPA lysis buffer containing 1 µM 
phenylmethylsulfonyl fluoride, and 40 µg of protein was subjected to electrophoresis on sodium 
dodecyl sulfate–polyacrylamide gels with a concentration gradient of 4% to 20% (Invitrogen). 
Membranes were incubated with primary antibodies anti-ABCA1 and anti-ABCG1 (Novus 
Biologicals, Littleton, CO). Actin antibody was used as a loading control.  
miR-33a and anti-miR-33a transfection  
SUM149 and KPL4 were transfected with 40 nM miRIDIAN miR-33a mimic (miR-33a) and 
SUM159 and MDA-MB-231 cells with 60 nM miRIDIAN miRNA inhibitor (anti-miR-33a) 
(Dharmacon, Lafayette, CO), utilizing Oligofectamine (Invitrogen), for 48 hours. All control 
samples were treated with an equal concentration of a non-targeting control mimic sequence or 
negative control inhibitor sequence to detect non–sequence-specific effects. miR-33a 
overexpression and knockdown were verified by using qRT-PCR as described above.  
Clonogenic survival assays 
Clonogenic viability of the breast cancer cells was tested in triplicate in standard monolayer 
conditions. Following 48 hours of miR-33a or anti-miR-33a transfection, cells were washed 
with phosphate-buffered saline solution (PBS) and supplemented with serum-free medium with 
or without 100 µg/mL of HDL for a total of 24 hours. After treatment with HDL, cells were 
irradiated and then incubated for 14 days. Cells were then subjected to crystal violet staining 
(10%) to mark colonies with 50 cells or more (≥300-µm diameter). Survival curves were 
obtained for all groups, and curves were fitted on the basis of the linear-quadratic model. Cells 
were irradiated by using a 137Cs source (Shepherd Irradiator, J.L. Shepherd and Associates, San 
Fernando, CA).  
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Patient outcomes 
The Oxford breast cancer dataset was downloaded from the U.S. National Center for 
Biotechnology Information (NCBI) GEO website (GSE22216).129 Expression values for miR-
33a (Probe set id = ILMN_3167691) and clinical characteristics for 210 cases were extracted. 
These data were subjected to a Cox regression model for distant recurrence-free survival 
duration (DRFS) with inclusion of the following covariates: patient age, tumor size and grade, 
nodal involvement, ER expression, and quartile of miR-33 expression. 
Statistical analysis 
For in vitro studies, statistical significance of differences between groups was determined by 
using the Student t-test and calculated by Origin software (OriginLab, Northampton, MA).  
 
4.4 Results 
miR-33 and cholesterol transporter expression levels are inversely correlated in breast 
cancer cells  
 We first set out to determine the expression levels of miR-33a and miR-33b in five 
breast cancer cell lines that represent a variety of breast cancer subtypes. The claudin-low breast 
cancer cell lines (SUM159 and MDA-231) had significantly higher miR-33a expression than the 
other cell lines, but only SUM159 had higher levels of both miR-33a and miR-33b expression 
(Figure 15A). As ABCA1 and ABCG1 are known targets of miR-33,128 we next tested the 
expression levels of these proteins in these cells through western blotting. Expression of 
ABCA1 and ABCG1 was inversely correlated with miR-33 expression in four of the five cell 
lines (Figure 15B).  
 Figure 15. Expression of miR
breast cancer cells were detected by qRT
expression was significantly higher in claudin
claudin-high cell lines (KPL4 and SUM149)
and SUM149 cells than in SUM159 and MDA
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HDL-induced radiation sensitivity is correlated with miR-33a expression 
 Our next experiments were designed to compare the impact of HDL on the sensitivity to 
radiation of the low miR-33a–expressing cell lines (SUM149 and KPL4) and the high miR-33a–
expressing cell lines (MDA-231 and SUM159). Treatment with HDL (100 µg/mL) for 24 hours 
radiosensitized the low miR-33a–expressing cell lines, as previously reported (Figure 
16A,B).120 In the high miR-33a–expressing cell lines MDA-231 and SUM159, however, HDL 
had a slight radioprotective effect (Figure 16 C, D). These results suggest that level of 
expression of miR-33a correlates with radiation sensitivity in response to HDL treatment in 
vitro.  
Targeting miR-33a expression alters HDL-induced radiation response  
To investigate the role of miR-33a in radiation sensitivity of breast cancer cells in 
response to HDL, we knocked down miR-33a in SUM159 and MDA-231; two breast cancer cell 
lines that express miR-33a endogenously (Figure 15A). Antagonism of endogenous miR-33a 
increased ABCA1 protein expression in both cell types (Figure 17A, B), resulting in 
radiosensitization of MDA-231 treated with HDL, a reversal of the results observed in wild-type 
cells (Figure 17C). Knockdown of miR-33a in SUM159 also resulted in radiosensitization in 
the presence of HDL (Figure 17D).  
 Next, transfection of SUM149 and KPL4 (low miR-33a–expressing cells) with miR-33a 
mimic decreased ABCA1 protein expression (Figure 18A, B). Overexpression of miR-33a 
resulted in the reversal of HDL-induced radiosensitization seen previously. Transfection of 
SUM149 cells with miR-33a mimic resulted in no change in the clonogenic survival following 
HDL treatment (Figure 18C), and a similar result was observed in KPL4 cells (Figure 18D).  
 Figure 16. Clonogenic survival curves indicate effect of miR
sensitivity of breast cancer cells.
MDA-MB-231, and (D) SUM159 breast cancer cells irradiated at different doses (x axis) with 
or without HDL pretreatment. HDL pretreatment comprised incubation for 24 hours with HDL 
100 µg/mL. After irradiation, colonies were allowed to form for 14 days. The surviving 
fractions with or without HDL at each dose of radiation are shown. 
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 Figure 17. Inhibition of miR
Knockdown of miR-33a in SUM159 and MDA
expression than in cells transfected with control oligonucleotides. (
assays of miR-33a knockdown MDA
different doses (x axis) with or without HDL pretreatment. HDL pretreatment comprised 
incubation for 24 hours with HDL 100 µg/mL. After irradiation, colonies were allowed to form 
for 14 days. The surviving fractions with or without HDL at each dose of radiation are shown.
 
 
89 
-33a increases HDL-induced radiation sensitivity. 
-MB-231 cell lines resulted in greater ABCA1 
C,D) Clonogenic survival 
-MB-231 and SUM159 breast cancer cells irradiated at 
 
(A,B) 
 
 Figure 18. Ectopic expression of miR
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These results led us to conclude that miR-33a regulates the radiation response to HDL in breast 
cancer cells.  
miR-33a expression in breast cancer patients predicts local recurrence 
We downloaded a previously published dataset from the NCBI GEO website to 
determine prognostic significance of miR-33 on DRFS 129. The 210 cases analyzed were 
separated into four quartiles based on miR-33a expression (Figure 19A). We tested for 
differences (log-rank test) in DRFS by miR-33a expression quartile and found a significant 
difference in DRFS between the highest and lowest quartiles (p=0.0228) (Figure 19B). 
Multivariate Cox regression analysis for DRFS revealed that patients in quartile 4 (greatest miR-
33a expression) had a DRFS hazard ratio of 2.0, which was nearly significantly higher than that 
of patients in quartile 1 (p=0.076). These results suggest that miR-33a expression warrants 
further investigation as a potential biomarker for breast cancer patient outcome.  
 
 
 
 
 
 
 
 
 Figure 19. High serum miR
patients. (A) Expression of miR
from the Oxford breast cancer dataset was separated into four quartiles. 
curves representing distant recurrence
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4.5 Discussion 
In this study, we found that expression of miR-33a was inversely correlated with HDL-
induced radiation sensitivity in breast cancer cells. Our results support the importance of 
cholesterol metabolism in breast cancer cells’ response to radiation therapy. 
 MiR-33 is expressed in various cell types and tissues, and miR-33 is a key regulator of 
cholesterol homeostasis by regulating the cholesterol transport that removes cholesterol stores 
from cells to HDL lipoproteins.128 Our results show that miR-33 expression varies in breast 
cancer cell lines. The regulation of intracellular cholesterol is complex and is influenced by 
genetic factors and by posttranscriptional mechanisms.130 ABCA1 functions as the primary 
gatekeeper in regulating removal of excess free cholesterol from tissues by effluxing cellular 
cholesterol to lipid-free apoA-1, resulting in the formation of HDL particles.131 ABCA1 is 
known to be associated with HDL from the observation that patients with ABCA1 mutations 
(i.e., Tangier disease) have a deficiency in plasma HDL.132  Recent studies showed evidence 
that miR-33 functions as a negative feedback loop triggered by low intracellular cholesterol. 
Transcription of miR-33 is stimulated under low sterol conditions and represses genes, including 
ABCA1 and ABCG1, that are involved in cholesterol export.37 Furthermore, that miR-33 controls 
both liver HDL biosynthesis and cellular efflux of cholesterol to nascent HDL particles has been 
shown by in vivo manipulation of miR-33 levels leading to changes in both circulating HDL 
levels and cellular cholesterol concentrations.37   
 In this study, we showed for the first time that targeting miR-33a expression in breast 
cancer cells can alter the effect of HDL on response to radiation. These conclusions were based 
on the response of four cell lines and so might not reflect processes in the intact body, although 
it was previously showed a strong correlation between in vitro radiation sensitivity and patient 
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radiation response.65 Inhibition of miR-33a increased the radiosensitization of high miR-33–
expressing breast cancer cell lines in response to HDL treatment, while promotion of miR-33a 
expression in low miR-33a–expressing breast cancer cell lines inhibited HDL-induced 
radiosensitization. The ability of miR-33 to negatively regulate genes that regulate cholesterol 
transport makes it an attractive potential target for cancer therapy. Targeting miR-33 may have 
the potential to both raise the level of circulating HDL and increase its radiosensitizing effect.  
Furthermore, since miRNAs can be rapidly measured in blood samples, our finding that miR-33 
can predict DRFS suggests that miR-33 is a potential biomarker for breast cancer outcome for 
patients with a high HDL level.   
4.6 Conclusions 
Our results reveal that miR-33 regulates HDL-induced radiosensitivity. 
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Chapter V 
Mesenchymal Stem Cells and Macrophage Cross-Talk through IL-6 to Promote 
Inflammatory Breast Cancer Cell Invasion and Self Renewal 
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5.1 Abstract 
Background: Inflammatory breast cancer (IBC) is responsible for 10% of breast cancer deaths. 
The hallmarks of IBC are skin involvement and a high propensity to metastasize. “Normal” 
breast tissue from women with an IBC diagnosis had significantly greater macrophage 
infiltration and increased cells with stem cell markers compared to non IBC “normal” breast 
tissue. These changes were present prior to diagnosis in two patients where pre-IBC biopsies 
were available. Therefore, we hypothesized changes in the normal breast microenvironment 
prior to tumor formation contributes to the IBC phenotype. 
Methods: To study our hypothesis we used a co-culture system to measure the interactions 
between normal macrophages (Raw 264.7 cell line), bone-marrow derived mesenchymal stem 
cells (MSCs), and IBC cells (SUM 149 and MDA-IBC3). Conditioned media (CM) from MSC 
culture was added to macrophages overnight. The macrophages were subsequently analyzed for 
their surface markers and cytokine production. Reciprocally, MSCs were “educated” by 
macrophages by co-culturing polarized M2 macrophages with MSCs at a 1:1 ratio. MSCs and 
cancer cells were co-cultured in trans-wells (Boyden chambers) for 24 hours. Migration and 
invasion in vitro was determined by adding MSCs or IBC cells to the insert of the trans-well and 
cultured in combination with either parental MSCs or educated MSCs for 24 hours.  After co-
culture, IBC cells were analyzed for their ability to invade and form mammospheres. For mouse 
models, SUM 149 cells and mesenchymal stem cells were co-injected orthotopically of 
immunocompromised mice on day 0. On day 1 and continuing weekly, either IgG or anti-CSF1 
antibodies were injected intraperitoneally up until the tumors reached a volume of 500 mm3.    
Results: The addition of MSC CM to the macrophage culture for 24 hours polarized the 
macrophages into a M2 phenotype expressing CD206 and arginase 1. When M2 macrophages 
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were co-cultured with MSCs, the number of MSCs migrating increased 2 fold with the addition 
of M2 macrophages compared to media alone, M1, or unstimulated macrophages (P<0.05). IBC 
cells showed a 2 fold enhancement of invasion towards M2 educated MSCs compared to either 
uneducated MSCs, or media alone (P<0.05). IBC cells co cultured with M2 educated MSCs 
grew 3 fold more mammospheres compared to IBC cells grown with uneducated MSCs 
(P<0.01).  Lastly, the addition of IL-6 neutralizing antibody or simvastatin inhibited the effects 
of educated MSCs on IBC cells. In vivo, the treatment with anti-CSF1 significantly delayed 
tumor growth and time to tumor resection compared to the IgG group. In addition the anti-CSF1 
group had fewer mice with skin invasion and local recurrence.  
Conclusions: Herein we demonstrate reciprocal tumor interactions between normal cells in the 
IBC microenvironment. MSC and macrophages can influence each other to increase the tumor 
promoting influence of each on IBC cells. Our results suggest IL-6 a mediator of these tumor 
promoting influences and is important for the IBC induced migration of MSCs.  
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5.2 Introduction 
Inflammatory breast cancer is a devastating, variant of breast cancer that presents with 
skin changes on the breast and spreads rapidly. These signs are caused by blockage of 
lymphatics and skin invasion, not by classic inflammation.12 To date, studies comparing IBC 
and non-IBC tumor cells have identified more similarities than differences. Our preliminary 
studies of non-tumor containing breast tissue at least 5 cm away from IBC tumor cells have 
identified interesting differences that the number of CD 68+ cells (macrophages) was 
significantly elevated in IBC normal adjacent tissues compared to non-IBC.133 In two cases 
where pre-malignancy biopsies were available, the macrophage infiltrate was demonstrated 10 
years prior to diagnosis suggesting the normal breast tissue was altered prior to the initiation of 
cancer. Macrophages are known to fall into two categories, Th1 stimulated pro-inflammatory or 
Th2 stimulated, anti-inflammatory.134 Tumor associated macrophages (TAMs) are prognostic in 
non-IBC and have been shown in vivo to promote lymphatic emboli, the hallmark of IBC.135 
The state and plasticity of macrophages (tumor or normal adjacent) in IBC patients and models 
has not been examined nor has their interaction with other cell types in the IBC stroma been 
examined. Lack of such knowledge is important because these cells are potentially mediators of 
field effects that lead to the clinical characteristics of IBC, and targets for prevention and 
treatment of IBC. 
We have shown that mammosphere cultured MSCs promote tumor stem cells and in 
vivo growth 136, and Liu et al have shown that ALDH1+ MSCs do the same.137 While numerous 
studies have demonstrated that MSCs mediate macrophage polarization and function 138 far 
fewer have looked at the impact of macrophages on MSCs. 
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We hypothesized that pre-malignant macrophage-educated MSCs in the breast mediate 
the IBC phenotype including diffuse migration, skin involvement, and treatment resistance. This 
hypothesis is based on our data demonstrating in vitro and in vivo data demonstrating MSCs 
promote stem cell surrogates and skin invasion of IBC, as well as published studies highlighting 
the role of macrophage-educated MSCs in supporting the hematopoietic stem cell niche.  
5.3 Materials and Methods 
Cell culture 
The IBC cell line SUM149 was obtained from Asterand (Detroit, MI, USA) and cultured in 
Ham’s F-12 media supplemented with 10% fetal bovine serum (FBS), 1 mg/mL hydrocortisone, 
5 mg/mL insulin, and 1% antibiotic-antimycotic. Human-derived bone marrow MSCs were 
obtained from EMD Millipore (Billerica, MA, USA) (Part #SCC034, Lot N61710996) and 
cultured in alpha minimum essential medium (MEM) supplemented with 20% FBS and 1% 
penicillin/streptomycin/glutamine. The mouse macrophage cell line RAW 264.7 was purchased 
from ATCC and maintained in DMEM supplemented with 10% FBS.  
Transwell co-culture assay 
5 × 104 of either breast cancer cells, macrophages, or MSCS/well were seeded in the lower 
compartment of 12 well transwell polyethylene terephthalate (PET) permeable supports or 75 
mm polycarbonate transwell inserts pore size 8 µm (Corning), respectively, and let to adhere 
overnight. The medium was replaced serum free media one hour before adding 5 × 104 of breast 
cancer cells, macrophages, or MSCS into the upper compartment of the transwell inserts. The 
co-cultures were incubated for 24 hours without medium change in a humidified chamber at 
37°C. 
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Migration and Invasion Assays 
Cells were assayed for their ability to migrate or invade using the cytoselect 24 well Cell 
Migration and Invasion Assay Kit (Cell Bio Labs). The Cell Migration portion of this kit uses 
polycarbonate membrane inserts (8 µm pore size) in a 24- well plate. The membrane serves as a 
barrier to discriminate migratory cells from non-migratory cells. 5.0 X 104 cells were seeded in 
the top of the insert on the membrane. Finally, the cells are removed from the top of the 
membrane and the migratory cells are stained with crystal violet and quantified. The Cell 
Invasion Assay portion of this kit uses a 24-well plate containing polycarbonate membrane 
inserts (8 µm pore size); the upper surface of the insert membrane is coated with a uniform layer 
of dried basement membrane matrix solution. This basement membrane layer serves as a barrier 
to discriminate invasive cells from non-invasive cells. Invasive cells are able to degrade the 
matrix proteins in the layer, and ultimately pass through the pores of the polycarbonate 
membrane. Finally, the cells are removed from the top of the membrane and the invaded cells 
are stained and quantified. 
Sphere Formation Assay 
To generate primary mammospheres, cells in monolayer culture were pre-treated with 
lipoproteins for 24 hours, and untreated cells were grown in standard mammosphere medium 
(serum-free, growth factor enriched medium). Low attachment plates were used as described 
previously [14]. For secondary mammosphere assay, cells from primary mammospheres were 
dispersed with 0.05% trypsin, seeded in ultra-low attachment plates (20,000 cells/ml) in 
mammosphere medium, incubated for seven days and counted. A concentration of 10 µg/mL 
was used in the in vitro experiments to simulate normal cholesterol lipoprotein levels found in 
human blood samples.  After 24 hours treated and untreated cells were suspended into single 
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cell suspension and plated in mammosphere conditions (further referred to as 3D culture) at 
concentration of 20,000 cells/mL. 
Co-injection of SUM149 cells with MSCs 
SUM149 cells were injected into the cleared mammary fat pads of female immunocompromised 
SCID/Beige mice (3 to 5 weeks old), with or without 5% MSCs, in a total of 2.5 × 105 cells 
per injection. SUM149 were labeled with dual luciferase-GFP reporter gene (pFULG) vector. 
For co-injections, 2.5 × 104 MSCs were premixed with SUM149 cells and the mixture co-
injected in the #4 (left side) mammary fat pad of the mice. Transplants were allowed to grow to 
500 mm3 (monitored with caliper measurements) and were then resected in a survival surgery. 
Follow-up of tumor-skin involvement and metastasis development 
Tumor-skin involvement was accessed visually during primary tumor growth (loss of fur at 
tumor site, redness and thickness of skin), during tumor excision (tumors firmly connected with 
skin) and after tumor resection (loss of fur, redness, and thickness of skin at any site). The 
development and localization of metastasis was monitored by bioimaging the luciferase signal 
(IVIS Spectrum system (Caliper Life Sciences, Hopkinton, MA, USA)). Findings between 
groups were compared with Fisher’s exact test. 
In vivo treatment with anti-CSF1 
After SUM149 cells with 10% MSCs had been injected into the cleared mammary fat pads of 
female immunocompromised SCID/Beige mice as described above, mice were injected 
intraperitoneally (IP) with either IgG or anti-CSF1 (a dose of 0.5 mg per injection), started on 
day 1 following injection of cells and continued for weekly up until the time of resection. 
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5.4 Results 
Characterizing the interactions between MSCs and macrophages in a co-culture system 
To characterize the differences in MSC activation under the influence of macrophages, 
we cultured RAW 241.7 mouse macrophage cells with human derived MSC cells in an in vitro 
transwell co-culture assay (Figure 20). The transwell setting allowed us to investigate the effect 
of soluble mediators on MSC activation since direct cell contact of these cells was inhibited by a 
polyethylene terephthalate (PET) membrane (pore size 8 µm). Macrophages grown for 24 hours 
in MSC CM displayed a higher of degree of M2 type markers in CD206 and Arginase-1 
compared with macrophages alone (Figure 21A). The MSCs grown in the M2 macrophage co-
culture migrated at a 2 fold increase compared to MSCs grown with serum alone, M0, or M1 
macrophages (p<0.05) (Figure 21B). Furthermore, The MSCs co-cultured with M2 macrophage 
co-culture secreted 1.6 fold more IL-6 compared to MSCs grown with serum alone, M0, or M1 
macrophages (p<0.05) (Figure 21C). To investigate the impact of M2 educated MSCs influence 
on IBC cells, we took MSCs from M2 co culture and co-cultured them with IBC cells for 24 
hours. We found M2 educated MSCs co-cultured with IBC cells (SUM149 and IBC3) migrated 
significantly more than uneducated MSCs compared with the controls (p<.05) (Figure 21D). 
This effect could be reversed with the addition of an anti-IL-6 antibody during the 24 hour co-
culture with IBC cells (Figure 21D).  
 
 Figure 20. Model of Co-Culture System. 
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Crosstalk between educated MSCs and IBC cells increases IBC invasion and self-renewal 
through IL-6 
We next investigated how the IBC cells would respond following 24 hours co-culture 
with M2 educated MSCs. The IBC cells co-cultured with M2 educated MSCs had a higher 
number of invading cells in both the uneducated and M2 educated MSCs co-culture in SUM149 
cells (Figure 22A). Only IBC3 cells grown in co-culture with M2 educated MSCs observed to 
have a 3 fold increase in invasion (Figure 22B). The increase in invasion of M2 educated MSCs 
was inhibited with the addition of the anti-IL-6 antibodies during the co-culture (Figure 22A, 
B). We next tested for mammosphere formation following co-culture. Both MSCs and M2 
educated MSCs increased SUM149 and IBC3 sphere formation efficiency, but only M2 
educated MSCs increased sphere formation to a 2 fold higher number compared to MSCs. Once 
again this effect on mammosphere formation could be blocked with anti-IL6 antibodies (Figure 
22 C, D).  
Simvastatin blocks IL-6 secretion and inhibits the effects of M2 educated MSCs on IBC 
invasion and self-renewal  
Numerous studies have shown that statins increase infiltrating macrophages in other 
diseases and recently Fujita et al further showed that statins also promote the pro-inflammatory 
macrophage subtypes in renal disease.139 Due to the large data showing statins have both an 
anti-tumor effect in breast cancer and also have the ability to alter the inflammatory response we 
tested the effects of statins in our co-culture system. Simvastatin significantly reduced by over 2 
fold the secretion of IL-6 in both uneducated and educated MSCs (Figure 23A).  
 Figure 22 Crosstalk between educated MSCs and IBC cells increases IBC invasion and 
self-renewal through IL-6. Following 24 hours of co
“educated” MSCs or parental MSCs were co
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basement membrane transwell after 24 hours was counted. Significant differences are shown as 
follows: *, P < 0.05 for unpaired 2
 
107 
-culture with M2 macrophages, the 
-cultured with (A) SUM149 or (
-IL6 antibodies. The number of IBC cells that invaded
-tailed Student’s t-test (n = 3). 
 
B) MDA-IBC3 for 
 through the 
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To test if simvastatin could inhibit the previous results mediated through IL-6 secretion, 
we designed an experiment wherein MSCs or M2 educated MSCs were first treated with 
simvastatin for 4 hours prior to being co-cultured with IBC cells for 24 hours. Half of the groups 
received simvastatin treated MSCs and the other half received both simvastatin treated MSCs 
and IL-6 cytokines. As observed before M2 educated MSCs significantly increased the number 
of mammospheres and invading cells. The treatment of the MSCs with simvastatin prior to co-
culture with SUM149 cells blocked the increase in both invasion and mammosphere formation. 
The rescue experiment with IL-6 reversed the effects of simvastatin on M2 educated MSC 
inhibition of SUM149 mammosphere and invasion (Figure 23 B, C).  
Blocking M2 macrophage recruitment in the in vivo IBC model delayed tumor formation 
and decreased 
Colony stimulating factor-1 (CSF1) is a key cytokine involved in recruitment and 
activation of tissue macrophages.140 Denardo et al showed an antibody against CSF1 blocked 
the binding of CSF1 to its CSF1 receptor and inhibited tumor associated macrophages (TAM) 
within the breast tumor.141 Cell suspensions of SUM149 cells and human bone marrow derived 
MSCs were prepared from monolayer cultures. In both groups, SUM149 and MSCs (9:1 ratio) 
were mixed and then co-injected into the mammary cleared fat pad as previously described.57 24 
hours following co-injection of tumor cells and MSCs, we started treatment with either anti-
CSF1 antibody or IgG intraperitoneally. We continued with injections of these antibodies 
weekly up until the week before resection of the tumor. 
 Figure 23. Simvastatin blocks IL
on IBC invasion and self-renewal
simvastatin or simvastatin plus IL
hours. (B) Following co-culture the the
basement membrane transwell after 24 hours was counted. Significant differences are shown as 
follows: *, P < 0.05 for unpaired 2
in self-renewal promoting suspension culture conditions. Significant differences are shown as 
follows: *, P < 0.05 for unpaired 2
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Monitoring tumor growth we observed that tumor latency was significantly shorter in the IgG 
treated mice (68.3 days vs. 124.4 days, P <.001; Figure 24A), and the time for the anti-CSF1 
group to reach 500 mm3 was slower than tumors in the control IgG group (105.7 days vs. 209.3 
days, P <0.001; Figure 24A). At the time of resection of the primary tumor, we recorded 
whether or not the tumor had grossly attached and invaded into the epidermis layer. The group 
of mice treated with anti-CSF1 had significantly less number of mice with invading tumors into 
the skin compared to the IgG (7/10 IgG vs 1/10 Anti-CSF1 p=0.02). Further, following resection 
we monitored for metastasis using live bioimaging to detect luciferase signal. Within 8 weeks, 
mice developed similar rates of spontaneous metastasis to the lung (not shown), but the IgG 
group had significantly more events of local recurrence compared to the anti-CSF1 group (9/10 
IgG vs 4/10 p=0.05) (Figure 24B). The tumors were collected following resection and stained 
with macrophage antibodies F4/80 and the M2 marker CD206 and analyzed by flow cytometry. 
The anti-CSF1 group had a lower percentage of F4/80+ cells compared to the IgG but the result 
was not significant (Figure 24C). However when analyzing the double positive F4/80+ 
CD206+ cells, the anti-CSF1 group had a significantly lower percentage of double positive 
cells, TAMs, compared to the IgG group (p<.01) (Figure 24D). This suggests the anti-CSF1 
antibody specifically blocks type 2 macrophage recruitment into the tumor.  
 
 
 
 Figure 24. Blocking M2 macrophage recru
suspensions of SUM149 cells and human bone marrow derived MSCs were prepared from 
monolayer cultures. In both groups, SUM149 and MSCs (9:1 ratio) were mixed and then co
injected into the mammary cleared fat pad as previously described. 24 hours following co
injection of tumor cells and MSCs, we started treatment with either anti
intraperitoneally. We continued with injections of these antibodies weekly up until the week 
before resection of the tumor.
of skin invasion and following tumor resection the presence of local recurrence was recorded. 
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5.5 Discussion 
Macrophages are a major component of the innate immunity and are distributed 
throughout every tissue. After circulating monocytes differentiate into macrophages they invade 
into tissues and increase immune reactions to the response of injury.142 In addition, macrophages 
remove cellular debris and clear dead or apoptotic cells.143 Macrophages can be polarized in the 
environment in response to different stimuli.144 The two classes of polarized macrophages are 
classically activated (M1) alternatively-activated (M2) macrophages.145 M1 and M2 secrete 
different cytokines, and M2 is known to secrete IL-10, TNF-α and IL-6.146  
Upon addition of MSC CM to macrophages, we observed an increase in expression of 
cell surface marker CD206 and Arginase 1, markers up-regulated in M2 macrophages. 
Additional studies by Ortiz etal. showed MSC-conditioned media inhibits the capacity of RAW- 
264.7 cells activated by silica or LPS to secrete TNFα 147, and Nemeth et al. investigated the 
effect of mouse BM-derived MSCs in a murine model of septicemia and showed LPS-
stimulated macrophages produced more IL-10 when co-cultured with BM-derived MSCs.148 In 
our study MSCs co-cultured with only M2 macrophages had an increased level of IL-6 
secretion. We speculate that this crosstalk between MSCs and macrophages (increasing the M2 
phenotype) and between M2 macrophages and MSCs (increasing the secretion of IL-6) can be a 
promoter of IBC. In fact, these M2 educated MSCs did enhance IBC cell invasion and 
mammosphere formation. IL-6 signaling in tumor cells increases tumor growth by promoting 
tumor invasiveness, metastasis and angiogenesis.149 Secretion of IL-6 leads to recruitment of 
metastatic cells out of the circulation to the primary tumor sites.150  
In addition to the effects on the tumor itself, recent studies show IL-6 controls tumor 
growth by activating the normal stromal cells located in the tumor microenvironment. For 
example, STAT3 activation initiated by IL-6 in tumor-associated endothelial cells, TAM, and 
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MSCs induces their ability to express VEGF and bFGF in a feed-forward loop that positively 
regulates angiogenesis within tumor tissues.151 Recent evidence suggests that MSCs coordinate 
with tumor cells that triggers increased IL-6 production, which correlates with accumulation of 
MSCs.152 
In a in vivo study, the combined treatment of MMTV-PyMT mice with PTX and anti-
CSF1 antibody slowed primary tumor development, reduced development of high-grade 
carcinomas, and decreased pulmonary metastasis by 85% and increased CD4+ and CD8+ T-cell 
infiltration in primary tumors. CSF1R blockade by PLX3397 depleted TAMs, but not 
neutrophils.153 Similarly in our in vivo experiment, CSF1 inhibition delayed SUM149 tumor 
initiation and reduced the percentage of TAMs (F4/80+ CD206+). Importantly since IBC is 
characterized by rapid skin involvement, the reduction we saw in skin invasion is noteworthy. 
These results suggest that the induction of the IBC phenotype with the addition of MSC cells is 
mediated by the host’s macrophage infiltration, specifically M2 macrophages. Future studies are 
warranted looking at targeting M2 type macrophages in patients with IBC. Our preliminary data 
suggest statins would be a well-tolerated FDA approved drug to begin with.  
5.6 Conclusions 
We demonstrate reciprocal tumor interactions between normal cells in the IBC 
microenvironment. MSC and macrophages can influence each other to increase the tumor 
promoting influence of each on IBC cells. Our results suggest IL-6 a mediator of these tumor 
promoting influences and  is important for the IBC induced migration of MSCs. Currently we 
are investigating the in vivo interactions between macrophages and MSCs in an orthotopic IBC 
mouse model. 
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6.1 Overall Conclusions 
 Taken together, the body of work presented here makes a strong case that cholesterol 
plays a major role in the pathogenesis of aggressive breast cancers. The therapeutic 
concentration of simvastatin inhibited TNBC cells in vitro CSC formation, invasion, and in vivo 
metastasis. The mechanism of action was shown to be through increasing the expression of 
FOXO3a, a tumor suppressor, by inhibiting its phosphorylation and subsequent degradation. 
Furthermore, FOXO3a mRNA in patients could predict for metastasis free survival. If the 
effects seen by simvastatin were through reducing cellular cholesterol concentrations, then one 
would expect to see the same effects with HDL, which removes cellular cholesterol. Indeed in 
Chapter 3, HDL removed cellular cholesterol and, as seen with simvastatin, blocked the 
phosphorylation of FOXO3a. HDL inhibited mammosphere formation and VLDL had the 
opposite effect in IBC cells in vitro. The translational piece to this study was the 
radiosensitization of IBC cells with HDL in vitro. This was shown to be caused by the increase 
in DNA damage after HDL treatment.  
 Not all breast cancers are alike. This was highlighted by the results in Chapter 4. The 
expression of miR-33 varied between breast cancer subtypes. In the IBC cells the expression of 
miR-33 was low and in the claudin low TNBC cells it was high. Since miR-33 regulates 
cholesterol efflux to HDL, we characterized the effects of HDL on each subtype with radiation 
treatment. We found that miR-33 regulates radiosensitivity to HDL treatment and that high 
miR-33 expression in patients predicted for poor outcomes. These results further show the 
importance of cholesterol in resistance to therapies.  
 Lastly co-culturing M2 macrophages and MSCs resulted in an “educated” MSC that in 
turn promoted IBC cell invasion and increased self-renewal. The educated MSCs secreted IL-6 
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which if blocked reversed the effects seen on invasion and self-renewal. Importantly, 
simvastatin inhibited the effects of educated MSCs on IBC cells by blocking IL-6 secretion. 
These results suggest that statins could be not only targeting the tumor cells, as shown in earlier 
chapters, but could have an additional anti-tumor effect by targeting the supporting stromal cells 
in the microenvironment.  
6.2 Research Significance 
 The significance of this thesis work is influential, from demonstrating the relevance of 
the effect of cholesterol regulation in aggressive breast cancer subtypes, identifying the impact 
of lipoproteins in radiation therapy, identifying biomarkers for tumors susceptible to this 
radiation therapy, and demonstrating the importance of normal cells that make up the IBC 
microenvironment.  
 Targeted therapies are the focus of cancer therapy today. This work suggests we might 
want to take a step back and look at some non-targeted therapies. Targeted pathways can be 
ineffective in cancer due to redundancy and cross talk between pathways that provide for 
resistance. Further, tumor heterogeneity provides increased difficulties in targeting single 
mutated genes. This thesis provides the framework to begin to study drugs, such as statins, that 
have multiple targets. These already FDA approved drugs can potentially be used in high risk 
populations to prevent cancer or in combination with current therapies to improve survival 
outcomes.  
 The key to harnessing the benefits of cholesterol targeting is designing appropriate 
clinical trials to address the questions raised in this work. From our work we know that patients 
with low HDL levels have worse outcomes and that HDL improves radiation sensitivity. An 
appropriate clinical trial would separate patients prior to radiation based on HDL levels. The 
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patients with low HDL should receive therapies driven to raise the levels of HDL prior to 
radiation therapy. Of course statins should be considered not only because of their potential 
positive HDL impact but on their impact on the tumors themselves. The patients with high HDL 
levels should be further analyzed for their miR-33 expression. We know that HDL has only an 
impact in cancer cells with low miR-33 expression. So in these patients with both high HDL and 
high miR-33, the strategy should be to block miR-33 before performing radiation.  
6.3 Future Investigations 
To explain the broad effects seen in these studies to one overarching mechanism, we 
must look at where cholesterol is utilized in the cell. Cholesterol is most predominating in the 
plasma membrane. Within the plasma membrane, cholesterol is heavily concentrated in lipid 
rafts. Lipid rafts are detergent-insoluble, sphingolipid- and cholesterol-rich membrane 
microdomains that form lateral assemblies in the plasma membrane.154,155 Lipid rafts also 
sequester glycophosphatidylinositol (GPI)-linked proteins and other signaling proteins and 
receptors, which may be regulated by their selective interactions with these membrane 
microdomains.156 Recent research has demonstrated that lipid rafts play a role in a variety of 
cellular processes — including the compartmentalization of cell-signaling events,157,158 the 
regulation of apoptosis159 and the intracellular trafficking of certain membrane proteins and 
lipids160  as well as in the infectious cycles of several viruses and bacterial pathogens.161,162 
Examining the formation and regulation of lipid rafts is a critical step in understanding these 
aspects of eukaryotic cell function. Several tools are available to study lipid rafts including: 
sucrose density centrifugation, immunoisolation of caveolae, and imaging with cholera-toxin B-
subunit which binds to the GM1 of the lipid raft.163 Comparing lipid raft composition in TNBC 
and IBC cells following statin and HDL treatment will provide us with the answer of whether 
targeting cholesterol disrupts lipid raft formation. Further using drugs that specifically target 
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lipid rafts, such as methyl-β-cyclodextrin, should recapitulate the findings we have observed 
with statins and HDL. Because of the importance of downstream signaling associated with lipid 
rafts this would be an important finding.  
Currently our lab is collecting cell lysates from a wide variety of breast cancer cell types 
and different treatment conditions among the subtypes. We are submitting these samples to a 
lipidomics core to provide analytics on what are the differences in lipids and cholesterol 
concentrations between breast cancer subtypes, differentiated vs undifferentiated, statin treated, 
HDL treated, and many more. These results should give us a better understanding of the 
potential targets for future studies. Other future studies should study the impact of cholesterol 
manipulation on radiation resistance in vivo. Importantly our lab has developed a brain 
metastasis model that was utilized in chapter 2. Interestingly the top overexpressed canonical 
pathways in brain derived metastasis were cholesterol biosynthesis related. The lab will perform 
in vivo brain metastatic experiments in dyslipidemic Apo E-/- mice. These experiments will 
reveal whether HDL levels can impact metastasis, like we showed with simvastatin. 
Lastly our lab will be interested in how the IBC microenvironment regulates radiation 
sensitivity and important signaling pathways, specifically FOXO3a. Co-cultured macrophages 
and MSCs will be cultured with IBC and TNBC cells and clonogenics performed to assess 
radiation sensitivity. Western blots will be performed on co-cultured educated MSC and tumor 
cells to assess the changes in FOXO3a expression following co-culture.  
Novel functions of cholesterol synthesis and metabolism are constantly being described, 
and my results combined with those of future studies will aid in developing new treatments for 
this important process. 
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Appendix 
Clinical Trial 
 This thesis has the potential to have an impact in the clinic. In order to successfully 
translate these results into positive patient outcomes, a well-designed clinical trial is needed. 
With any clinical trial, enrolling the proper patient population is important. I therefore propose a 
phase 2 study with which to evaluate patients at highest risk of relapse—IBC and TNBC breast 
cancer patients with minimal residual disease (i.e., the presence of ≥1 circulating tumor cells 
[CTCs]) after neoadjuvant chemotherapy. Minimal residual disease has been shown to be 
negatively prognostic, with median progression-free survival (PFS) duration of 18 months in 
TNBC and IBC patients. 
Primary and Secondary Objectives 
a. Primary objective: Detect a positive signal of long-term use of post-diagnosis 
simvastatin, 40 mg daily, on distant metastasis free survival (DMFS) and local 
recurrence (LR) following post-mastectomy radiation therapy (PMRT) in a high-
risk IBC and TNBC population. 
b. Secondary objective: Explore the underlying mechanisms for statin efficacy via 
cancer signaling pathways and cholesterol pathway. Establish if lipid profiles 
influence the effects of simvastatin and if miR-33 and FOXO3a expression is a 
predictor to response with simvastatin.  
Study Design 
 We would initially enroll approximately 125
currently receiving statin treatment or
completing neoadjuvant chemotherapy and have 
population). We will check the lipid profile and exclude patients with elevated lipid levels 
already on a statin; this group will be placed in observational arm and
with statin as indicated by the latest AHA lipid treatment guidelines. The remaining patients will 
receive simvastatin at 40 mg daily and will be monitored for 2 years; our goal is to enroll 
patients into this experimental arm.
Primary and Secondary Endpoints/Criteria for Evaluation
a. Primary endpoint: Estimated 
and physical examination every 6 months by a physician
b. Secondary endpoint: 
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i. Overall survival 
ii. Locoregional recurrence to assess efficacy of statin as radiosensitizer 
iii. Toxic effects of simvastatin in breast cancer population 
iv. Comparison of DMFS between experimental and observational arms to 
assess the importance of lipids in pathophysiology 
v. Change in the number of CTCs 
vi. Change in biomarkers (miR-33 and FOXO3a) measured in CTCs and 
serum 
This clinical trial we will allow us to obtain several answers from the pre-clinical data. First and 
most important we will answer whether patients that present with TNBC or IBC that have 
dyslipidemia that receive a statin prior to radiation will lower metastasis and improve local 
control? Importantly, this clinical trial will allow us to determine if statins effects are dependent 
on dyslipidemia or if lipoproteins are unimportant for their anti-tumor effects. We hypothesize 
that lipoproteins are critical for the potential beneficial effects of simvastatin.  
 We will obtain tumor biopsies and determine expression of miR-33 and FOXO3a and 
will correlate their expression to the outcomes from patients taking simvastatin. This will allow 
us to determine if the expression of these markers impact statin survival. In the patients already 
on statins (observational arm) we will be able to determine if miR-33 or FOXO3a effect survival 
and possible in the future it will be important to try to modulate their expression in addition to 
prescribing a statin.  
 
 Investigating the effects of sta
 
Figure A1. SUM 149 Cells were treated with simvastatin, U
inhibitor), or simvastatin and mevalonate for 24 hours and then stained with fillipin. Cholesterol 
is more equally dispersed in the plasma membrane in the DMSO and simvastatin +
group. In the simvataitn and U
cytoplasm.  
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tins on breast cancer cells 
-186661 (a cholesterol transport 
-18666A groups, the cholesterol is more concentrated in the 
 
 mevalonate 
 Figure A2. Simvastatin was added to cell culture of three cell lines for 24 hours. The cells after 
simvastatin treatmeant appear
126 
 more mesenchymal.  
 
 Figure A3. Simvastatin changes the mesenchymal and epilthelial markers.
Figure A4. Simvastatin inhibits mammosphere formation in MCF7 cells.
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 Figure A5. Simvastatin EC50 concentrations for SUM 149 and KPL4. The EC50 is well above 
the concentrations used in experiements. 
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 Figure A6. Simvastatin inhibited pEGFR mo
statin to inhibit pAkt. 
Figure A7. Simvastatin inhibited mammospheres and radiation increased mammosphere 
formation. Simvastatin inhibited the p
129 
re than any other statin. Simvastatin
-EGFR in both controls and radiation treated cells.
 
 was the only 
 
 
 Figure A8. The combination of simvastatin and erolotinib inhibits the phosphorylation of RhoA 
and EGFR in SUM 149 cells. The SUM 159 cells had full inhibition of 
or erlotinib.  
130 
pEGFR after simvastatin 
 
 Figure A9. Simvastatin and erolotinib in comibination inhibits both SUM 149 and SUM 159 
mammospheres more than either drug alone. Treatmeant with statins in combination with 
increasing erolotinib concentrations ha
alone.  
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d more of an effect on MTT activity then erolotinib 
 
  
Figure A10. The combination of simvastatin and erolotinib radiosensitizes SUM 149 cells more 
than either drug alone. No effects seen in combination for SUM 159 cells. 
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 Figure A11. The effects of lipoproteins and apolipoproteins on SUM 149 and MCF7 
mammosphre formation.  
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 Anaylzing the effects of polarization on macrophages and MSCs
Figure A12. Raw 264.7 macrophage cells were stimulated with LPS or IL
treated with +/- simvastatin. The cell supernatant was used for ELISAs of TNF
cytokine), IL-1 beta (M1), or IL
TNF-alpha and blocked cytokine secretion of IL
134 
 
-4 for 24 hours and 
-10 (M2 cytokine). Simvastatin increased the effects of LPS on 
-1 beta. 
 
-alpha (M1 
 Figure A13. MSC cells were po
(A) MSC 2 (IL-4 treated) migration was inhibited by simvastatin. (B) MSC1 (LPS) 
mammosphres were inhibited by simvastatin. (C) MSC1 and MSC2 proliferation was inhibited 
by simvastatin.  
135 
larized with either LPS (MSC1) or IL-4 (MSC2) for 24 hours. 
 
 Figure A14. Raw cell supernatants was submitted for lumi
(LPS treated) macrophages had high cytokine secretion profile while the M2 (IL
cytokine secretion. The untreated Raw cells grown in MSC conditioned media (CM) for 24
hours had very high IL-6 secretion.
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nex magnetic bead assay. The M1 
  
 
-4) had low 
 
 Figure A15. The morphology of macrophges (Raw cells) under light microscope after 
polarization for 24 hours.  MSC CM turns macrophages into a M2 morphology with long 
pertusions.  
 
137 
 
 Figure A16. Raw cell lysates submitted for western blotting and probed with anti
antibody (M2 marker). Raw cells have high expression at baseline of arginase 1 suggesting Raw 
cells at baseline are M2 like. 
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-Arginase 1 
 Figure A17. The macrophage morphology changes 
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after 24 hours of MSC CM culture.
 
  
  
Figure A18. miR-33a inhibition in TNBC cells leads to increased FOXO3a expression.
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